<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Orthop Surg Traumatol</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Orthop Surg Traumatol</journal-id><journal-title-group><journal-title>European Journal of Orthopaedic Surgery &#x00026; Traumatology</journal-title></journal-title-group><issn pub-type="ppub">1633-8065</issn><issn pub-type="epub">1432-1068</issn><publisher><publisher-name>Springer Paris</publisher-name><publisher-loc>Paris</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407910</article-id><article-id pub-id-type="pmc">PMC12102120</article-id>
<article-id pub-id-type="publisher-id">4322</article-id><article-id pub-id-type="doi">10.1007/s00590-025-04322-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Adipose- and bone marrow-derived stromal cells reduce pain in patients with knee osteoarthritis but do not substantially improve knee functionality: an updated systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Hohmann</surname><given-names>Erik</given-names></name><address><email>ehohmann@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Keough</surname><given-names>Natalie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stokes</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Frank</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rodeo</surname><given-names>Scott</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00g0p6g84</institution-id><institution-id institution-id-type="GRID">grid.49697.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 2298</institution-id><institution>Medical School, Faculty of Health Sciences, </institution><institution>University of Pretoria, </institution></institution-wrap>Pretoria, South Africa </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01a77tt86</institution-id><institution-id institution-id-type="GRID">grid.7372.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 8809 1613</institution-id><institution>University of Warwick, </institution></institution-wrap>Coventry, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02hh7en24</institution-id><institution-id institution-id-type="GRID">grid.241116.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0790 3411</institution-id><institution>University of Colorado Denver, </institution></institution-wrap>Denver, US </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03zjqec80</institution-id><institution-id institution-id-type="GRID">grid.239915.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2285 8823</institution-id><institution>Hospital for Special Surgery, </institution></institution-wrap>New York, US </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>35</volume><issue>1</issue><elocation-id>214</elocation-id><history><date date-type="received"><day>26</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>25</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To perform a systematic review and meta-analysis of randomized and comparative studies comparing mesenchymal stromal cells other orthobiological injections for patients with knee osteoarthritis. </p></sec><sec><title>Methods</title><p id="Par2">Systematic review of Medline, Embase, Scopus, and Google Scholar, including all level 1&#x02013;3 from 2014 to 2024. Validated scores (VAS, KOOS, Lysholm, IKDC) were included as outcome measures. Risk of bias was assessed using the Cochrane Collaboration&#x02019;s tools. The GRADE system was used to assess the quality of the body of evidence and the modified Coleman Methodology score was used to assess study quality. Heterogeneity was assessed using &#x003c7;<sup>2</sup> and I<sup>2</sup> statistics. </p></sec><sec><title>Results</title><p id="Par3">Ten studies were included; all published in English between 2019 and 2023, encompassing a total of 563 cases (281 treated with MSCs and 282 with other biologics). Two studies had a high risk of bias, one had some bias, and seven had a low risk of bias. Publication bias was detected (Egger's test 3.26447; <italic>p</italic>&#x02009;=&#x02009;0.007). The pooled estimates revealed significant differences favoring MSCs for VAS scores at 3, 6, and 12&#x000a0;months. For KOOS pain and symptoms, significant differences were observed at 3 and 6&#x000a0;months.</p></sec><sec><title>Conclusion</title><p id="Par4">The results of this meta-analysis demonstrated a significant effect of adipose and bone marrow-derived stromal cell injections on pain reduction at all assessed time points, and showed superiority over other non-surgical treatment options. These differences were not reflected in clinical and functional outcomes, indicating that the observed reduction in pain did not correspond to substantial improvements in knee functionality.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00590-025-04322-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Adipose derived stem cells</kwd><kwd>Adipose derived stromal cells</kwd><kwd>Bone marrow derived stromal cells</kwd><kwd>Bone marrow derived stem cells</kwd><kwd>Knee osteoarthritis</kwd><kwd>Orthobiologics</kwd></kwd-group><funding-group><award-group><funding-source><institution>University of Pretoria</institution></funding-source></award-group><open-access><p>Open access funding provided by University of Pretoria.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag France SAS, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Conservative treatment of osteoarthritis remains a challenging problem. The American College of Rheumatology/Arthritis Foundation Guidelines for the management of osteoarthritis of the hand, hip and knee provided strong recommendations for treatment [<xref ref-type="bibr" rid="CR1">1</xref>]. They determined that exercise, weight loss, tibiofemoral bracing, topical nonsteroidal anti-inflammatory drugs, and intra-articular steroid injections are strongly supported by evidence [<xref ref-type="bibr" rid="CR1">1</xref>]. Similarly, the 2019 OARSI guidelines for the non-surgical management of knee osteoarthritis recommend weight management, exercise programs, topical and systemic anti-inflammatory drugs, and intra-articular injections with hyaluronic acid and corticosteroids [<xref ref-type="bibr" rid="CR2">2</xref>]. These first-line interventions are effective regardless of other variables such as age, sex, BMI, severity of osteoarthritis, and the presence of depression and other comorbidities [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par6">The use of orthobiologics, regenerative therapies, and other intra-articular high molecular weight hyaluronic acid has gained substantial attention in recent years [<xref ref-type="bibr" rid="CR4">4</xref>]. These therapies include platelet-rich plasma (PRP), stromal cells such as mesenchymal stromal cells (MSCs) and adipose-derived cells (ADSCs), bone marrow aspirate, stromal vascular fraction, micro-fragmented adipose tissue, and cells derived from peri-natal tissues, including umbilical cord blood, amniotic fluid, and placental-derived cells [<xref ref-type="bibr" rid="CR4">4</xref>]. The principal mechanism of action of orthobiologics is that they primarily alleviate symptoms, likely due to their anti-inflammatory and immune-modulating effects, rather than inducing true tissue regeneration [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par7">The application of intra-articular injections with MSCs has recently been proposed as a feasible alternative treatment option [<xref ref-type="bibr" rid="CR5">5</xref>]. Several clinical studies involving MSCs failed to demonstrate functional improvement or pain relief compared to other orthobiologics and placebo [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. In contrast, other publications showed that autologous MSCs led to significant pain relief and functional improvements at 6&#x000a0;months compared to placebo [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par8">The purpose of this study was therefore to perform a systematic review and meta-analysis of randomized controlled and comparative observational studies comparing MSCs and other available orthobiological injections for patients with knee osteoarthritis.</p></sec><sec id="Sec2"><title>Material and methods</title><p id="Par9">This study adhered to the Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [<xref ref-type="bibr" rid="CR12">12</xref>], along with the updated guidelines outlined in the Cochrane Handbook [<xref ref-type="bibr" rid="CR13">13</xref>].</p><sec id="Sec3"><title>Eligibility criteria</title><p id="Par10">This project included studies comparing autologous and cultured adipose- and bone-marrow-derived stromal cells to other orthobiologic interventions including platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), synthetic agents like hyaluronic acid, corticosteroid injections, and placebos, provided they met specific inclusion and exclusion criteria. Level I&#x02013;III evidence studies were eligible for inclusion if they were published between January 2014 and June 2024. Level III evidence studies were considered for inclusion to augment sample size and enhance generalizability of the results [<xref ref-type="bibr" rid="CR14">14</xref>]. Previous research has indicated that incorporating Level III evidence studies does not alter the risk estimate of treatment effects derived from meta-analyses of randomized controlled trials, observational studies, or a combination of both [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. Additionally, studies comparing more than two interventions were included in the analysis. For analysis, each intervention was then compared to the ADSC/BMSC treatment arm. </p><p id="Par11">Additional inclusion criteria comprised symptomatic knee osteoarthritis (Kellgren Grade I&#x02013;IV), mean participant age exceeding 40&#x000a0;years, a minimum follow-up duration of 6&#x000a0;months, and inclusion of at least one validated outcome score (such as KOOS, VAS, IKDC, Lysholm). Studies involving patients who had previously received knee injections prior to study commencement or had these agents administered as adjuvant treatment with or without knee surgery within the past 6&#x000a0;months were excluded. Clinical case level of evidence (LOE) IV studies, case series, abstracts, and conference proceedings were likewise excluded. If the LOE was not specified in the manuscript, the level of evidence was determined as per standard research guidelines [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec4"><title>Literature search</title><p id="Par12">A systematic review of the literature was performed to identify all publications in English and German, screening the databases Medline, Embase, Scopus, and Google Scholar. These databases were screened using the following terms and Boolean operators: &#x0201c;orthobiologics&#x0201d; AND/OR &#x0201c;platelet-rich plasma&#x0201d; AND/OR &#x0201c;PRP&#x0201d; AND/OR &#x0201c;bone marrow aspirate concentrate&#x0201d;; AND/OR &#x0201c;BMAC&#x0201d; AND/OR &#x0201c;hyaluronic acid&#x0201d; AND/OR &#x0201c;adipose stem cells injections&#x0201d; AND/OR &#x0201c;adipose stromal cells injections&#x0201d;, AND/OR &#x0201c;knee osteoarthritis&#x0201d;; AND/OR &#x0201c;degenerative knee&#x0201d;. For the Medline search the MeSH term &#x0201c;osteoarthritis, knee&#x0201d; was used with the following qualifiers: drug therapy and therapy. One reviewer conducted independent title and abstract screening. Disagreements between reviewers were resolved by consensus, and if no consensus was reached, they were carried forward to the full-text review. All eligible articles were manually cross-referenced to ensure that other potential studies were identified.</p></sec><sec id="Sec5"><title>Data extraction and quality assessment</title><p id="Par13">An electronic data extraction form was utilized to gather information from each article, including level of evidence, country, age, sex, length of follow-up, sample size, clinical outcome scores, range of motion, and complications. Risk of bias was assessed using the Cochrane Collaboration&#x02019;s Risk of Bias Tool [<xref ref-type="bibr" rid="CR13">13</xref>]. The GRADE system was used by three reviewers to assess the quality of the body of evidence for each outcome measure [<xref ref-type="bibr" rid="CR13">13</xref>]. The recommendations from the Cochrane Handbook were followed, and an initial level of certainty was assigned. Studies were downgraded if there was a high risk of bias, inconsistency and imprecision of the results, and indirectness of evidence. Studies were upgraded if there were large treatment effects, a dose&#x02013;response, or reasons to oppose plausible residual bias and confounding effects. Any disagreement between reviewers was resolved by consensus and/or by arbitration between the two senior authors. The modified Coleman Methodology Score was used as a second validated instrument to assess the quality of the included studies. The score ranges from 0 to 100 and the final score was categorized as excellent (85&#x02013;100 points), good (70&#x02013;84 points), fair (55&#x02013;60 points), and poor (&#x0003c;&#x02009;55 points) [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par14">Inter-observer differences for study eligibility and risk of bias were measured using Cohen&#x02019;s kappa coefficient. Heterogeneity of the data was assessed using &#x003c7;2 and I<sup>2</sup> statistics. Outcomes were pooled using a random effects model if the I<sup>2</sup> statistic was&#x02009;&#x0003e;&#x02009;25%, and a fixed model was used if the statistic was&#x02009;&#x0003c;&#x02009;25%. Pooling of data for clinical outcomes was only performed if a minimum of three studies were available. If standard deviations were not reported the standard deviation was calculated using the following formula: SD&#x02009;=&#x02009;max&#x02013;min/4 [<xref ref-type="bibr" rid="CR21">21</xref>]. If the included studies did not include tables describing their outcome measures of central tendency and variations, the first author was contacted, and results were requested. All tests of significance were two-tailed, and an &#x003b1; of less than 0.05 was considered significant. If more than ten studies were included, publication bias was assessed in accordance with the guidelines outlined in the Cochrane Handbook. In such instances, funnel plots, Egger&#x02019;s regression test and Kendall's tau with continuity correction were subsequently employed [<xref ref-type="bibr" rid="CR13">13</xref>]. Funnel and forest plots, and all statistical analyses, were performed using STATA SE (Version 13.0; StataCorp, College Station, Texas, USA) for Windows, and the comprehensive meta-analysis software package (CMA), version 3 (Biostat Inc, Englewood, NJ, USA).</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Study selection and characteristics</title><p id="Par15">The initial literature search identified 1576 studies for consideration. Of those, 621 studies were excluded for duplication, and the titles and abstracts of the remaining 946 publications were checked for eligibility. Five hundred twenty-three (n&#x02009;=&#x02009;523) studies were excluded after inspection of the titles. These studies were either published study protocols, basic science studies, clinical studies using other non-cultured preparation, or narrative reviews. Of the remaining 423 studies, the abstracts were examined and a further 281 studies were excluded. Of the remaining 142 studies, 39 publications were excluded as they comprised systematic reviews and meta-analyses. Additionally, 19 studies were excluded because they either employed multiple injections, combined various biologics or used stromal vascular fraction (SVF) or micro-fragmented adipose tissue (MFAT) as mesenchymal stromal cells. Furthermore, 74 studies were excluded as they were classified as level IV clinical studies. After all exclusions, ten (n&#x02009;=&#x02009;10) studies met all the eligibility criteria and were included in the analysis (Supplementary Fig.&#x000a0;1) [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. All ten studies were published in English between 2019 and 2023 with a cumulative total of 563 cases. A total of 281 patients were treated with MSC&#x02019;s and 282 patients were treated with other biologics. The study characteristics are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Summary of the Study Characteristics of Level I and II studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Authors</th><th align="left">LOE</th><th align="left">Country</th><th align="left">MSC</th><th align="left">Patients (n)</th><th align="left">Control</th><th align="left">Patients (n)</th><th align="left">Follow-up<break/>(months)</th><th align="left">Outcomes MFAT-Control</th></tr></thead><tbody><tr><td align="left">Lamo-Espinoza 2016</td><td align="left">II</td><td align="left">Spain</td><td align="left"><p>BM-MSC 100&#x000a0;ml iliac crest</p><p>Surface markers for identification: CD 90, CD73, CD 44. Absent Markers: CD34, CD45</p><p>20&#x02009;&#x000d7;&#x02009;10<sup>6</sup> 3.0&#x000a0;ml injected</p></td><td align="left"><p>N&#x02009;=&#x02009;10</p><p>F&#x02009;=&#x02009;6, M&#x02009;=&#x02009;4</p><p>Mean age 65.9</p></td><td align="left">4&#x000a0;ml HA (Hyalone&#x000ae;)</td><td align="left"><p>N&#x02009;=&#x02009;10</p><p>F&#x02009;=&#x02009;3&#x000a0;M&#x02009;=&#x02009;7</p><p>Mean Age 60.3</p></td><td align="left">12</td><td align="left"><p><bold>WOMAC Pain MSC Control</bold></p><p>Base 4.5(4&#x02013;5) 5.5(5&#x02013;6)</p><p>3/12 3(2&#x02013;5) 3.5(3&#x02013;7)</p><p>6/12 3.5(2&#x02013;5) 2.5(1&#x02013;5)</p><p>12/12 2.5(2&#x02013;4) 3.5(3&#x02013;5)</p><p><bold>WOMAC Stiffness MSC Control</bold></p><p>Base 2.5(2&#x02013;4) 2(1&#x02013;3)</p><p>3/12 2(1&#x02013;2) 2(1&#x02013;2)</p><p>6/12 2(1&#x02013;3) 0.5(0&#x02013;2)</p><p>12/12 2(1&#x02013;3) 2(1&#x02013;2)</p><p><bold>WOMAC Function MSC Control</bold></p><p>Base 19(12&#x02013;25) 21(13&#x02013;24)</p><p>3/12 10(7&#x02013;18) 9(7&#x02013;11)</p><p>6/12 14.5(8&#x02013;17) 7.5(2&#x02013;13)</p><p>12/12 11(9&#x02013;14) 9.5(5&#x02013;23)</p><p><bold>WOMAC Total MSC Control</bold></p><p>Base 28(16&#x02013;34) 29(19&#x02013;38)</p><p>3/12 13(11&#x02013;26) 12(11&#x02013;14)</p><p>6/12 20(13&#x02013;23) 10(4&#x02013;20)</p><p>12/12 16.5(12&#x02013;19) 13.5(8&#x02013;33)</p><p><bold>VAS MSC Control</bold></p><p>Base 7 (5&#x02013;8) 5(3&#x02013;7)</p><p>3/12 4 (2&#x02013;6) 3(2&#x02013;5)</p><p>6/12 3 (1&#x02013;5) 5 (2&#x02013;8)</p><p>12/12 2 (0&#x02013;4) 4 (3&#x02013;5)</p></td></tr><tr><td align="left">Bastos 2019</td><td align="left">II</td><td align="left">Portugal</td><td align="left"><p>BM-MSC iliac crest</p><p>CFU-F assay&#x02009;+&#x02009;flow cytometry</p></td><td align="left"><p>N&#x02009;=&#x02009;16</p><p>F&#x02009;=&#x02009;6, M&#x02009;=&#x02009;10</p><p>Mean age</p><p>55.7</p></td><td align="left">Corticosteroid</td><td align="left"><p>N&#x02009;=&#x02009;17</p><p>F&#x02009;=&#x02009;8, M&#x02009;=&#x02009;9</p><p>Mean age 55.9</p></td><td align="left">12</td><td align="left"><p><bold>KOOS Pain MSC Control</bold></p><p>Base 34.5&#x02009;+&#x02009;11.4 40.5&#x02009;+&#x02009;19.6</p><p>12/12 56.8&#x02009;+&#x02009;26.6 59.5&#x02009;+&#x02009;22.2</p><p><bold>KOOS Symptoms MSC Control</bold></p><p>Base 41.5&#x02009;+&#x02009;18.4 47.7&#x02009;+&#x02009;17.9</p><p>12/12 61.6&#x02009;+&#x02009;22.5 56.1&#x02009;+&#x02009;22.3</p><p><bold>KOOS ADL MSC Control</bold></p><p>Base 31.7&#x02009;+&#x02009;19.1 40.7&#x02009;+&#x02009;21.0</p><p>12/12 58.4&#x02009;+&#x02009;27.5 61.6&#x02009;+&#x02009;24.4</p><p><bold>KOOS Sports MSC Control</bold></p><p>Base 13.0&#x02009;+&#x02009;21.0 18.0&#x02009;+&#x02009;28.0</p><p>12/12 36.6&#x02009;+&#x02009;29.5 36.2&#x02009;+&#x02009;31.7</p><p><bold>KOOS QOL MSC Control</bold></p><p>Base 16.8&#x02009;+&#x02009;12.4 16.5&#x02009;+&#x02009;16.5</p><p>12/12 40.2&#x02009;+&#x02009;25.9 32.0&#x02009;+&#x02009;29.3</p><p><bold>KOOS Total MSC Control</bold></p><p>Base 30.3&#x02009;+&#x02009;13.1 36.9&#x02009;+&#x02009;17.8</p><p>12/12 54.2&#x02009;+&#x02009;24.7 54.4&#x02009;+&#x02009;22.7</p></td></tr><tr><td align="left">Freitag 2019</td><td align="left">I</td><td align="left">Australia</td><td align="left"><p>60&#x000a0;ml adipose tissue</p><p>Surface markers for identification: CD 90, CD73, CD 105</p><p>3.0&#x000a0;ml single injection</p><p>100&#x02009;&#x000d7;&#x02009;10<sup>6</sup> ADMSC</p></td><td align="left"><p>N&#x02009;=&#x02009;10</p><p>F&#x02009;=&#x02009;6, M&#x02009;=&#x02009;4</p><p>Mean age 54.7</p></td><td align="left">Simple analgesia, weight management, exercise</td><td align="left"><p>N&#x02009;=&#x02009;10</p><p>F&#x02009;=&#x02009;8, M&#x02009;=&#x02009;2</p><p>Mean age 59.1</p></td><td align="left">12</td><td align="left"><p><bold>WOMAC Total MSC Control</bold></p><p>Base 59.6&#x02009;+&#x02009;17.9 58.8&#x02009;+&#x02009;12.8</p><p>3//12 82.6&#x02009;+&#x02009;11.3 65.7&#x02009;+&#x02009;9.1 6/12 83&#x02009;+&#x02009;9.9 64.4&#x02009;+&#x02009;12.2</p><p>12/12 84&#x02009;+&#x02009;9.4 59.1&#x02009;+&#x02009;12.8</p><p><bold>KOOS Pain MSC Control</bold></p><p>Base 53&#x02009;+&#x02009;14.5 52.8&#x02009;+&#x02009;10.8 3/12 77.4&#x02009;+&#x02009;15.8 54.9&#x02009;+&#x02009;7.4</p><p>6/12 76.4&#x02009;+&#x02009;12.4 55.3&#x02009;+&#x02009;11.4</p><p>12/12 77.3&#x02009;+&#x02009;11.3 48.9&#x02009;+&#x02009;12.7</p><p><bold>KOOS Symptoms MSC Control</bold></p><p>Base 63.6&#x02009;+&#x02009;21.3 46.1&#x02009;+&#x02009;11</p><p>3/12 79.6&#x02009;+&#x02009;12.9 48.1&#x02009;+&#x02009;13.1</p><p>6/12 80.1&#x02009;+&#x02009;13.7 45.3&#x02009;+&#x02009;13</p><p>12/12 84.3&#x02009;+&#x02009;9.4 47.9&#x02009;+&#x02009;13.6</p><p><bold>KOOS ADL MSC Control</bold></p><p>Base 58.8&#x02009;+&#x02009;19.8 59.4&#x02009;+&#x02009;13.6</p><p>3/12 82.5&#x02009;+&#x02009;12.3 67.1&#x02009;+&#x02009;9.8</p><p>6/12 83.6&#x02009;+&#x02009;9.6 65.5&#x02009;+&#x02009;14.4</p><p>12/12 84.3&#x02009;+&#x02009;9.4 60.7&#x02009;+&#x02009;13.5</p><p><bold>KOOS Sports MSC Control</bold></p><p>Base 39&#x02009;+&#x02009;26.2 26&#x02009;+&#x02009;20.4</p><p>3/12 63.8&#x02009;+&#x02009;22.5 27.5&#x02009;+&#x02009;21.9</p><p>6/12 66.9&#x02009;+&#x02009;15.3 31&#x02009;+&#x02009;29.8</p><p>12/12 70&#x02009;+&#x02009;17.8 31.5&#x02009;+&#x02009;33</p><p><bold>KOOS QOL MSC Control</bold></p><p>Base 29.4&#x02009;+&#x02009;20.5 30.1&#x02009;+&#x02009;15.9</p><p>3/12 51.6&#x02009;+&#x02009;23.7 29.9&#x02009;+&#x02009;14.6</p><p>6/12 63.3&#x02009;+&#x02009;12.2 31.9&#x02009;+&#x02009;19.7</p><p>12/12 61.8&#x02009;+&#x02009;13 33.9&#x02009;+&#x02009;18.9</p><p><bold>VAS MSC Control</bold></p><p>Base 6.5 6.5</p><p>3/12 2.6 6</p><p>6/12 2.8 6</p><p>12/12 2.7 6</p></td></tr><tr><td align="left">Lee 2019</td><td align="left">I</td><td align="left">Poland</td><td align="left"><p>20&#x000a0;ml adipose tissue</p><p>Surface markers for identification: CD 31,CD34, CD45, CD 73, CD90</p><p>1&#x02009;&#x000d7;&#x02009;10<sup>8</sup> 3.0&#x000a0;ml injected</p></td><td align="left"><p>N&#x02009;=&#x02009;12</p><p>F&#x02009;=&#x02009;9, M&#x02009;=&#x02009;3</p><p>Mean age</p><p>62.2</p></td><td align="left">3&#x000a0;ml Saline</td><td align="left"><p>N&#x02009;=&#x02009;12</p><p>F&#x02009;=&#x02009;9, M&#x02009;=&#x02009;3</p><p>Mean age 63.2</p></td><td align="left">6</td><td align="left"><p><bold>WOMAC Total MSC Control</bold></p><p>Base 60&#x02009;+&#x02009;17.0 56</p><p>3/12 39 57 6/12 26.7&#x02009;+&#x02009;13.3 52</p><p><bold>WOMAC Pain MSC Control</bold></p><p>Base 15 16</p><p>3/12 6 11 6/12 5 10</p><p><bold>WOMAC Stiffness MSC Control</bold></p><p>Base 6 6</p><p>3/12 4 5 6/12 2 4</p><p><bold>WOMAC Function MSC Control</bold></p><p>Base 40 47</p><p>3/12 29 37 6/12 33 20</p><p><bold>VAS MSC Control</bold></p><p>Base 7 6</p><p>3/12 5 6 6/12 4 6</p><p><bold>KOOS Pain MSC Control</bold></p><p>Base 5 5</p><p>3/12 6 5 6/12 8 6</p><p><bold>KOOS Symptoms MSC Control</bold></p><p>Base 46 46</p><p>3/12 63 47 6/12 70 49</p><p><bold>KOOS ADL MSC Control</bold></p><p>Base 50 54</p><p>3/12 63 58 6/12 71 61</p><p><bold>KOOS Sports MSC Control</bold></p><p>Base 19 28</p><p>3/12 34 27 6/12 48 30</p><p><bold>KOOS QOL MSC Control</bold></p><p>Base 25 32</p><p>3/12 45 45 6/12 58 40</p><p><bold>VAS MSC Control</bold></p><p>Base 6.8 5.4</p><p>3/12 4.5 5.2</p><p>6/12 3.4 5.2</p></td></tr><tr><td align="left">Lu 2019</td><td align="left">II</td><td align="left">China</td><td align="left"><p>Re-Join&#x000ae; Liposuction</p><p>Characterized according to ISCT</p></td><td align="left"><p>N&#x02009;=&#x02009;26</p><p>F&#x02009;=&#x02009;23, M&#x02009;=&#x02009;3</p><p>Mean age 55.0</p></td><td align="left">HA: ARTZ 25&#x000a0;mg/25&#x000a0;ml</td><td align="left"><p>N&#x02009;=&#x02009;26</p><p>F&#x02009;=&#x02009;23, M&#x02009;=&#x02009;3</p><p>Mean age 59.6</p></td><td align="left">12</td><td align="left"><p><bold>WOMAC Total MSC Control</bold></p><p>Base 30.83&#x02009;+&#x02009;19.14 34.17&#x02009;+&#x02009;17.16</p><p>6/12 21.7&#x02009;+&#x02009;17.87 27.58&#x02009;+&#x02009;16.93 12/12 21.35&#x02009;+&#x02009;18.19 27.25&#x02009;+&#x02009;16.33</p><p><bold>WOMAC Pain MSC Control</bold></p><p>Base 7.7&#x02009;+&#x02009;4.1 7.2&#x02009;+&#x02009;3.7</p><p>6/12 5.1&#x02009;+&#x02009;3.1 5.9&#x02009;+&#x02009;3.6 12/12 4.7&#x02009;+&#x02009;3.4 5.9&#x02009;+&#x02009;3.4</p><p><bold>WOMAC Stiffness MSC Control</bold></p><p>Base 2.4&#x02009;+&#x02009;1.9 2.6&#x02009;+&#x02009;1.8</p><p>6/12 1.7&#x02009;+&#x02009;2.1 2.1&#x02009;+&#x02009;1.8 12/12 1.6&#x02009;+&#x02009;2.2 2.2&#x02009;+&#x02009;1.8</p><p><bold>WOMAC Function MSC Control</bold></p><p>Base 23.6&#x02009;+&#x02009;14.6 22.3&#x02009;+&#x02009;13.3</p><p>6/12 17.0&#x02009;+&#x02009;13.4 18.5&#x02009;+&#x02009;12.8 12/12 15.7&#x02009;+&#x02009;13.4 18.2&#x02009;+&#x02009;12.2</p><p><bold>VAS MSC Control</bold></p><p>Base 5.4&#x02009;+&#x02009;2.3 4.9&#x02009;+&#x02009;2.5</p><p>6/12 2.8&#x02009;+&#x02009;2.6 4.2&#x02009;+&#x02009;2.6</p><p>12/12 2.8&#x02009;+&#x02009;2.6 4.4&#x02009;+&#x02009;2.4</p></td></tr><tr><td align="left"><p>Yokota 2019</p><p>Koos 4</p></td><td align="left">III</td><td align="left">Japan</td><td align="left"><p>Adipose Tissue-Derived Cultured Stem Cells</p><p>100&#x000a0;ml liposuction</p><p>12.8 mill cells for knee injection</p></td><td align="left"><p>N&#x02009;=&#x02009;42</p><p>F&#x02009;=&#x02009;33, M&#x02009;=&#x02009;9</p><p>Mean age 70</p></td><td align="left">Stromal Vascular Fraction</td><td align="left"><p>N&#x02009;=&#x02009;38</p><p>F&#x02009;=&#x02009;31, M&#x02009;=&#x02009;7</p><p>Mean age 73</p></td><td align="left">6</td><td align="left"><p><bold>KOOS Pain MSC Control</bold></p><p>Base 50 42</p><p>3/12 62 60 6/12 60 62</p><p><bold>KOOS Symptoms MSC Control</bold></p><p>Base 54 45</p><p>3/12 60 58 6/12 67 64</p><p><bold>KOOS ADL MSC Control</bold></p><p>Base 60 60</p><p>3/12 68 68 6/12 68 74</p><p><bold>KOOS Sports MSC Control</bold></p><p>Base 18 20</p><p>3/12 30 24 6/12 24 34</p><p><bold>KOOS QOL MSC Control</bold></p><p>Base 25 19</p><p>3/12 43 43 6/12 40 30</p><p><bold>VAS MSC Control</bold></p><p>Base 7 8</p><p>3/12 4 5 6/12 3 4</p></td></tr><tr><td align="left">Lamo Espinoza 2020</td><td align="left">II</td><td align="left">Spain</td><td align="left"><p>BM-MSC iliac crest</p><p>Surface markers for identification: CD 90, CD73, CD 44</p><p>Absent Markers: CD34, CD45</p><p>Flow cytometry</p></td><td align="left"><p>N&#x02009;=&#x02009;24</p><p>F&#x02009;=&#x02009;8, M&#x02009;=&#x02009;16</p><p>Mean age 54</p></td><td align="left"><p>PRP</p><p>PRGF-Endoret</p></td><td align="left"><p>N&#x02009;=&#x02009;26</p><p>F&#x02009;=&#x02009;9, M&#x02009;=&#x02009;17</p><p>Mean age 56</p></td><td align="left">12</td><td align="left"><p><bold>VAS MSC Control</bold></p><p>Base 5.3&#x02009;+&#x02009;1.9 5&#x02009;+&#x02009;1.8</p><p>3/12 3.8&#x02009;+&#x02009;2 3.8&#x02009;+&#x02009;1.6 6/12 3.3&#x02009;+&#x02009;2.2 3.5&#x02009;+&#x02009;2</p><p>12/12 3.5&#x02009;+&#x02009;2.5 4.5&#x02009;+&#x02009;2.2</p><p><bold>WOMAC Total MSC Control</bold></p><p>Base 33.4&#x02009;+&#x02009;18.7 31.9&#x02009;+&#x02009;16.2</p><p>3/12 24.4&#x02009;+&#x02009;17.4 21.7&#x02009;+&#x02009;17.1</p><p>6/12 21.3&#x02009;+&#x02009;16.6 23&#x02009;+&#x02009;15 12/12 16.7&#x02009;+&#x02009;11.6 22.3&#x02009;+&#x02009;15.8</p><p><bold>WOMAC Pain MSC Control</bold></p><p>Base 7.7&#x02009;+&#x02009;4.1 7.2&#x02009;+&#x02009;3.7</p><p>6/12 5.1&#x02009;+&#x02009;3.1 5.9&#x02009;+&#x02009;3.6 12/12 4.7&#x02009;+&#x02009;3.4 5.9&#x02009;+&#x02009;3.4</p><p><bold>WOMAC Stiffness MSC Control</bold></p><p>Base 3.3&#x02009;+&#x02009;2.1 3&#x02009;+&#x02009;1.6</p><p>3/12 2.3&#x02009;+&#x02009;2.2 1.9&#x02009;+&#x02009;1.4</p><p>6/12 2&#x02009;+&#x02009;1.9 2.2&#x02009;+&#x02009;1.6 12/12 2.1&#x02009;+&#x02009;1.9 2.1&#x02009;+&#x02009;1.6</p><p><bold>WOMAC Function MSC Control</bold></p><p>Base 23.5&#x02009;+&#x02009;13.2 22.3&#x02009;+&#x02009;12.8</p><p>3/12 17.6&#x02009;+&#x02009;12.6 15.5&#x02009;+&#x02009;12.6</p><p>6/12 14.9&#x02009;+&#x02009;11.8 16.3&#x02009;+&#x02009;11.1</p><p>12/12 23&#x02009;+&#x02009;16.6 22.3&#x02009;+&#x02009;15.8</p></td></tr><tr><td align="left">Ho 2022</td><td align="left">II</td><td align="left">Hongkong</td><td align="left"><p>BM-MSC</p><p>Histology</p></td><td align="left"><p>N&#x02009;=&#x02009;10</p><p>F&#x02009;=&#x02009;4, M&#x02009;=&#x02009;6 Mean age 56.7</p></td><td align="left"><p>HA</p><p>6&#x000a0;ml Synvisc</p></td><td align="left"><p>N&#x02009;=&#x02009;10</p><p>F&#x02009;=&#x02009;8, M&#x02009;=&#x02009;16</p><p>Mean age 54</p></td><td align="left">12</td><td align="left"><p><bold>VAS MSC Control</bold></p><p>Base 2.5&#x02009;+&#x02009;0.7 1.5&#x02009;+&#x02009;0.6</p><p>3/12 2.2&#x02009;+&#x02009;1.6 3.1&#x02009;+&#x02009;2.0 6/12 2.0&#x02009;+&#x02009;3.0 3.9&#x02009;+&#x02009;2.0</p><p>12/12 2.0&#x02009;+&#x02009;3.8 4.2&#x02009;+&#x02009;2.1</p><p><bold>WOMAC Total MSC Control</bold></p><p>Base 40.7&#x02009;+&#x02009;26 38.1&#x02009;+&#x02009;20.2</p><p>3/12 38.6&#x02009;+&#x02009;15.5 29.6&#x02009;+&#x02009;14.8</p><p>6/12 33.6&#x02009;+&#x02009;24.2 37.7&#x02009;+&#x02009;22.2</p><p>12/12 30.3&#x02009;+&#x02009;17.4 29.8&#x02009;+&#x02009;20.3</p><p><bold>WOMAC Pain MSC Control</bold></p><p>Base 8.2&#x02009;+&#x02009;5.4 7.6&#x02009;+&#x02009;3</p><p>3/12 8.0&#x02009;+&#x02009;4.0 6.0&#x02009;+&#x02009;2.2</p><p>6/12 7.1&#x02009;+&#x02009;5.7 7.2&#x02009;+&#x02009;3.2 12/12 6.4&#x02009;+&#x02009;4.5 4.4&#x02009;+&#x02009;3.2</p><p><bold>WOMAC Stiffness MSC Control</bold></p><p>Base 3.8&#x02009;+&#x02009;2.5 4.2&#x02009;+&#x02009;1.9</p><p>3/12 3.7&#x02009;+&#x02009;1.5 3.2&#x02009;+&#x02009;2.4</p><p>6/12 3.1&#x02009;+&#x02009;2.1 2.8&#x02009;+&#x02009;2.9 12/12 3.3&#x02009;+&#x02009;1.6 3.9&#x02009;+&#x02009;2.5</p><p><bold>WOMAC Function MSC Control</bold></p><p>Base 28.7&#x02009;+&#x02009;18.7 32.9&#x02009;+&#x02009;15.17</p><p>3/12 27.0&#x02009;+&#x02009;10.9 27.0&#x02009;+&#x02009;13.2</p><p>6/12 23.4&#x02009;+&#x02009;16.9 24.9&#x02009;+&#x02009;25.8</p><p>12/12 20.6&#x02009;+&#x02009;12.2 30.3&#x02009;+&#x02009;18.3</p></td></tr><tr><td align="left">Schweich 2022</td><td align="left">II</td><td align="left">Brasil</td><td align="left"><p>adipose tissue</p><p>Flow Cytometry</p><p>Pro: CD105, CD90, CD34, CD133</p></td><td align="left"><p>N&#x02009;=&#x02009;6</p><p>F&#x02009;=&#x02009;2, M&#x02009;=&#x02009;4 Mean age 48.0</p></td><td align="left"><p>PRP</p><p>18&#x000a0;ml blood</p><p>1500&#x000a0;rpm: 10&#x000a0;min 2000&#x000a0;rpm:15&#x000a0;min</p></td><td align="left"><p>N&#x02009;=&#x02009;6</p><p>F&#x02009;=&#x02009;2, M&#x02009;=&#x02009;4 Mean age 58.5</p></td><td align="left">6</td><td align="left"><p><bold>VAS MSC Control</bold></p><p>Base 2.5&#x02009;+&#x02009;0.7 1.5&#x02009;+&#x02009;0.6</p><p>6/12 2.0&#x02009;+&#x02009;3.0 3.9&#x02009;+&#x02009;2.0</p></td></tr><tr><td align="left">Kim 2023</td><td align="left">I</td><td align="left">Korea</td><td align="left"><p>Adipose tissue</p><p>CD312, CD 34, CD45</p><p>CD73, CD90</p><p>3&#x000a0;ml 1&#x02009;&#x000d7;&#x02009;10<sup>8</sup> in 3&#x000a0;ml saline</p></td><td align="left"><p>N&#x02009;=&#x02009;125</p><p>F&#x02009;=&#x02009;39,&#x02009;=&#x02009;86</p><p>Mean age 63.7</p></td><td align="left">Normal Saline 3&#x000a0;ml</td><td align="left"><p>N&#x02009;=&#x02009;127</p><p>F&#x02009;=&#x02009;26,M&#x02009;=&#x02009;101</p><p>Mean age 63.8</p></td><td align="left">6</td><td align="left"><p><bold>WOMAC Total MSC Control</bold></p><p>Base 55.0&#x02009;+&#x02009;15.9 51.7&#x02009;+&#x02009;15.9</p><p>3/12 35.1&#x02009;+&#x02009;18.7 38.0&#x02009;+&#x02009;17.2</p><p>6/12 33.3&#x02009;+&#x02009;18.6 37.4&#x02009;+&#x02009;19.2</p><p><bold>WOMAC Pain MSC Control</bold></p><p>Base 10.7&#x02009;+&#x02009;3.3 11.3&#x02009;+&#x02009;3.2</p><p>3/12 8.7&#x02009;+&#x02009;4.1 8.6&#x02009;+&#x02009;3.8</p><p>6/12 6.4&#x02009;+&#x02009;4.0 8.6&#x02009;+&#x02009;4.4</p><p><bold>WOMAC Stiffness MSC Control</bold></p><p>Base 4.5&#x02009;+&#x02009;1.3 4.9&#x02009;+&#x02009;1.5</p><p>3/12 3.1&#x02009;+&#x02009;1.8 3.6&#x02009;+&#x02009;1.6</p><p>6/12 2.7&#x02009;+&#x02009;1.9 3.6&#x02009;+&#x02009;1.9</p><p><bold>WOMAC Function MSC Control</bold></p><p>Base 39.8&#x02009;+&#x02009;9.4 41.8&#x02009;+&#x02009;10.3</p><p>3/12 26.5&#x02009;+&#x02009;18.7 32.1&#x02009;+&#x02009;12.1</p><p>6/12 18.1&#x02009;+&#x02009;18.6 27.5&#x02009;+&#x02009;19.2</p><p><bold>VAS MSC Control</bold></p><p>Base 57.7&#x02009;+&#x02009;17.1 60.9&#x02009;+&#x02009;16.6</p><p>3/12 35.5&#x02009;+&#x02009;24.6 47.7&#x02009;+&#x02009;23.7</p><p>6/12 32.5&#x02009;+&#x02009;24.6 46.6&#x02009;+&#x02009;19.2</p><p><bold>KOOS Pain MSC Control</bold></p><p>Base 50.1&#x02009;+&#x02009;13.9 46.9&#x02009;+&#x02009;16.2</p><p>3/12 34.8&#x02009;+&#x02009;18.2 35.8&#x02009;+&#x02009;17.2 6/12 33.8&#x02009;+&#x02009;17.0 36.9&#x02009;+&#x02009;17.1</p><p><bold>KOOS Symptoms MSC Control</bold></p><p>Base 55.7&#x02009;+&#x02009;15.9 51.7&#x02009;+&#x02009;15.9</p><p>3/12 44.7&#x02009;+&#x02009;18.3 42.9&#x02009;+&#x02009;17.0 6/12 40.7&#x02009;+&#x02009;17.9 41.9&#x02009;+&#x02009;17.5 <bold>KOOS ADL MSC Control</bold></p><p>Base 53.7&#x02009;+&#x02009;14.8 50.2&#x02009;+&#x02009;17.0</p><p>3/12 38.0&#x02009;+&#x02009;18.6 39.8&#x02009;+&#x02009;16.5 6/12 40&#x02009;+&#x02009;17.3 39.2&#x02009;+&#x02009;17.0</p><p><bold>KOOS Sports MSC Control</bold></p><p>Base 23.6&#x02009;+&#x02009;18.3 21.5&#x02009;+&#x02009;19.0</p><p>3/12 10.1&#x02009;+&#x02009;21.7 16.9&#x02009;+&#x02009;21.6 6/12 7.6&#x02009;+&#x02009;22.4 15.6&#x02009;+&#x02009;20.0</p><p><bold>KOOS QOL MSC Control</bold></p><p>Base 32.9&#x02009;+&#x02009;14.3 31.8&#x02009;+&#x02009;16.1</p><p>3/12 20.3&#x02009;+&#x02009;16.4 5.9&#x02009;+&#x02009;14.9 6/12 19.5&#x02009;+&#x02009;17.3 23.3&#x02009;+&#x02009;15.6</p></td></tr></tbody></table><table-wrap-foot><p>50.1</p></table-wrap-foot></table-wrap></p><sec id="Sec8"><title>Risk of bias cochrane assessment tool version 2</title><p id="Par16">Two studies were assessed as having a high risk of bias due to confounding [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. One study had some risk of bias [<xref ref-type="bibr" rid="CR24">24</xref>] due to confounding, missing data and bias in the measurements of outcome. The remaining seven studies had a low risk of bias (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>].<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Risk of bias robins cochrane risk of bias assessment tool version 2</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Authors</th><th align="left">LOE</th><th align="left">Bias due to confounding</th><th align="left">Bias in Selection of Participants</th><th align="left">Bias in Classification of interventions</th><th align="left">Bias due to deviations from Intended Interventions</th><th align="left">Bias due to missing data</th><th align="left">Bias in Measurement of outcomes</th><th align="left">Bias in Selection of the Reported Results</th><th align="left">Overall bias</th></tr></thead><tbody><tr><td align="left">Lamo Espinoza</td><td align="left">II</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td></tr><tr><td align="left">Bastos 2019</td><td align="left">II</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Moderate</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td></tr><tr><td align="left">Freitag 2019</td><td align="left">II</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Moderate</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td></tr><tr><td align="left">Lee 2019</td><td align="left">II</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td></tr><tr><td align="left">Lu 2019</td><td align="left">II</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td></tr><tr><td align="left">Yokota 2019</td><td align="left">III</td><td align="left">High</td><td align="left">Some</td><td align="left">Some</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">High</td></tr><tr><td align="left">Lamo Espinoza 2020</td><td align="left">II</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td></tr><tr><td align="left">Ho 2022</td><td align="left">II</td><td align="left">Some</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Some</td><td align="left">Some</td><td align="left">Low</td><td align="left">Some</td></tr><tr><td align="left">Schweich 2022</td><td align="left">II</td><td align="left">High</td><td align="left">Low</td><td align="left">Low</td><td align="left">Moderate</td><td align="left">Moderate</td><td align="left">Moderate</td><td align="left">Low</td><td align="left">High</td></tr><tr><td align="left">Kim 2023</td><td align="left">II</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec9"><title>Publication bias</title><p id="Par17">The funnel plot exhibited asymmetry in the standard deviations of the means, suggesting the presence of publication bias (Supplementary Fig.&#x000a0;2). This finding is corroborated by Egger's regression test, which yielded an intercept of 3.26447 with a t-value of 3.75116 and a <italic>p </italic>value of 0.00716. Additionally, Kendall's tau with continuity correction showed a tau coefficient of 0.58 with a <italic>p</italic> value of 0.02857, further supporting the indication of publication bias.</p></sec><sec id="Sec10"><title>Quality assessment</title><p id="Par18">The Grade quality assessment is summarized in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. Nine included studies were initially categorized as high level of certainty [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>] and one study was categorized as low level of certainty [<xref ref-type="bibr" rid="CR30">30</xref>]. The study by Yokota [<xref ref-type="bibr" rid="CR30">30</xref>] was a Level 3 comparative observational study with no randomization. Due to the high risk of bias, two studies [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were downgraded to a very low level of certainty. Three studies [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>] were downgraded to a moderate level of certainty due to some inconsistency and imprecision of results. The remaining five studies maintained their initial high level of certainty in the assessment [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. Given the overall high and moderate final level of certainty, the confidence in the effect estimate is therefore moderate to high and it is likely that the true effect may not be substantially different from the estimate of the effect.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Quality assessment using the cochrane GRADE system</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Authors</th><th align="left">LOE</th><th align="left">Initial level of certainty</th><th align="left">Final level of certainty</th><th align="left">Risk of bias</th><th align="left">Inconsistency of results</th><th align="left">Indirectness of evidence</th><th align="left">Imprecision of Results</th><th align="left">Large Effects (Upgrading)</th><th align="left">Dose Response<break/>(Upgrading)</th><th align="left">Opposing Plausible residual Bias and confounding (upgrading)</th></tr></thead><tbody><tr><td align="left">Lamo Espinoza</td><td align="left">II</td><td align="left">High</td><td align="left">High</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Low</td></tr><tr><td align="left">Bastos 2019</td><td align="left">II</td><td align="left">High</td><td align="left">Moderate</td><td align="left">Low</td><td align="left">Some</td><td align="left">Low</td><td align="left">Low</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Low</td></tr><tr><td align="left">Freitag 2019</td><td align="left">II</td><td align="left">High</td><td align="left">Moderate</td><td align="left">Low</td><td align="left">Some</td><td align="left">Low</td><td align="left">Low</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Low</td></tr><tr><td align="left">Lee 2019</td><td align="left">II</td><td align="left">High</td><td align="left">High</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Low</td></tr><tr><td align="left">Lu 2019</td><td align="left">II</td><td align="left">High</td><td align="left">High</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Low</td></tr><tr><td align="left">Yokota 2019</td><td align="left">III</td><td align="left">Low</td><td align="left">Very Low</td><td align="left">High</td><td align="left">Low</td><td align="left">Some</td><td align="left">Low</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Low</td></tr><tr><td align="left">Lamo Espinoza 2020</td><td align="left">II</td><td align="left">High</td><td align="left">High</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Low</td></tr><tr><td align="left">Ho 2022</td><td align="left">II</td><td align="left">High</td><td align="left">Moderate</td><td align="left">Some</td><td align="left">Low</td><td align="left">Low</td><td align="left">Some</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Low</td></tr><tr><td align="left">Schweich 2022</td><td align="left">II</td><td align="left">High</td><td align="left">Very Low</td><td align="left">High</td><td align="left">Some</td><td align="left">Low</td><td align="left">Some</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Low</td></tr><tr><td align="left">Kim 2023</td><td align="left">II</td><td align="left">High</td><td align="left">High</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Low</td></tr></tbody></table></table-wrap></p><p id="Par19">Quality assessment using the CMS score (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) revealed that only three out of the ten included studies were of high quality [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. The primary limitations of these studies were the short mean follow-up period, small sample size, and inadequate description of the post-intervention rehabilitation protocol. Five studies [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] were assessed as having good study quality. Similar to the low-quality studies, the main limitations included a short mean follow-up period, small sample size, and inadequate description of the post-intervention rehabilitation protocol. Only two studies [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were assessed as having fair quality, with limitations also related to the previously mentioned issues.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Modified Coleman methodology score</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Authors</th><th align="left">Total points</th><th align="left">Study size</th><th align="left">Mean follow-Up</th><th align="left">Percent of patients with follow-up</th><th align="left">Number of interventions</th><th align="left">Type of study</th><th align="left">Diagnostic certainty</th><th align="left">Description surgical technique</th><th align="left">Description post op rehabilitation</th><th align="left">Outcome criteria</th><th align="left">Procedures for assessing outcomes</th><th align="left">Description of subject selection</th></tr></thead><tbody><tr><td align="left">Lamo Espinoza 2016</td><td align="left">73</td><td align="left">0</td><td align="left">0</td><td align="left">5</td><td align="left">10</td><td align="left">15</td><td align="left">5</td><td align="left">5</td><td align="left">0</td><td align="left">7</td><td align="left">11</td><td align="left">15</td></tr><tr><td align="left">Bastos 2019</td><td align="left">94</td><td align="left">4</td><td align="left">0</td><td align="left">5</td><td align="left">10</td><td align="left">15</td><td align="left">5</td><td align="left">5</td><td align="left">10</td><td align="left">10</td><td align="left">15</td><td align="left">15</td></tr><tr><td align="left">Freitag 2019</td><td align="left">75</td><td align="left">4</td><td align="left">0</td><td align="left">5</td><td align="left">10</td><td align="left">15</td><td align="left">5</td><td align="left">5</td><td align="left">3</td><td align="left">7</td><td align="left">11</td><td align="left">10</td></tr><tr><td align="left">Lee 2019</td><td align="left">72</td><td align="left">4</td><td align="left">0</td><td align="left">5</td><td align="left">10</td><td align="left">15</td><td align="left">5</td><td align="left">5</td><td align="left">0</td><td align="left">7</td><td align="left">11</td><td align="left">10</td></tr><tr><td align="left">Lu 2019</td><td align="left">75</td><td align="left">4</td><td align="left">0</td><td align="left">5</td><td align="left">10</td><td align="left">15</td><td align="left">5</td><td align="left">3</td><td align="left">0</td><td align="left">7</td><td align="left">11</td><td align="left">15</td></tr><tr><td align="left">Yokota 2019</td><td align="left">67</td><td align="left">10</td><td align="left">0</td><td align="left">5</td><td align="left">10</td><td align="left">0</td><td align="left">5</td><td align="left">3</td><td align="left">3</td><td align="left">10</td><td align="left">6</td><td align="left">15</td></tr><tr><td align="left">Lamo Espinoza 2020</td><td align="left">77</td><td align="left">4</td><td align="left">0</td><td align="left">5</td><td align="left">10</td><td align="left">15</td><td align="left">5</td><td align="left">5</td><td align="left">0</td><td align="left">7</td><td align="left">11</td><td align="left">15</td></tr><tr><td align="left">Ho 2022</td><td align="left">84</td><td align="left">4</td><td align="left">0</td><td align="left">5</td><td align="left">10</td><td align="left">15</td><td align="left">5</td><td align="left">5</td><td align="left">0</td><td align="left">10</td><td align="left">15</td><td align="left">15</td></tr><tr><td align="left">Schweich 2022</td><td align="left">67</td><td align="left">4</td><td align="left">0</td><td align="left">5</td><td align="left">10</td><td align="left">15</td><td align="left">5</td><td align="left">5</td><td align="left">0</td><td align="left">7</td><td align="left">11</td><td align="left">5</td></tr><tr><td align="left">Kim 2023</td><td align="left">85</td><td align="left">10</td><td align="left">0</td><td align="left">5</td><td align="left">10</td><td align="left">15</td><td align="left">5</td><td align="left">5</td><td align="left">0</td><td align="left">10</td><td align="left">15</td><td align="left">10</td></tr><tr><td align="left">Overall Mean</td><td align="left">77</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec11"><title>Outcome scores: VAS</title><p id="Par20">The clinical outcomes for VAS for all studies are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Nine studies reported on baseline figures and the pooled estimates did not demonstrate significant between group differences (SMD 0.395, 95% CI &#x02212;&#x02009;0.033 to 0.823, <italic>p</italic>&#x02009;=&#x02009;0.07, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;76%; Supplementary Fig.&#x000a0;3) [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par21">Seven studies were included to analyse VAS at 3&#x000a0;months [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The pooled estimate demonstrated significant between group differences in favour of MSC (SMD &#x02212;&#x02009;0.526; 95% CI &#x02212;&#x02009;0.713 to &#x02212;&#x02009;0.339, <italic>p</italic>&#x02009;=&#x02009;0.0001, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;64%; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Forest Plot comparing VAS at 3&#x000a0;months demonstrated between group significant differences (<italic>p</italic>&#x02009;=&#x02009;0.0001) in favor of MSCs</p></caption><graphic xlink:href="590_2025_4322_Fig1_HTML" id="MO1"/></fig></p><p id="Par22">Nine studies were included to analyze VAS at 6&#x000a0;months [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>] The pooled estimate demonstrated significant between group differences in favour of MSC (SMD &#x02212;&#x02009;0.767; 95% CI &#x02212;&#x02009;0.946 to &#x02212;&#x02009;0.588, <italic>p</italic>&#x02009;=&#x02009;0.0001, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;63%; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Forest Plot comparing VAS at 6&#x000a0;months demonstrated between group significant differences (<italic>p</italic>&#x02009;=&#x02009;0.0001) in favor of MSCs</p></caption><graphic xlink:href="590_2025_4322_Fig2_HTML" id="MO2"/></fig></p><p id="Par23">Five studies were included to analyze VAS at 12&#x000a0;months [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. The pooled estimate demonstrated significant between group differences in favour of MSC (SMD &#x02212;&#x02009;0.952; 95% CI &#x02212;&#x02009;1.491 to &#x02212;&#x02009;0.413; <italic>p</italic>&#x02009;=&#x02009;0.001, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;58%; Supplementary Fig.&#x000a0;4).</p></sec><sec id="Sec12"><title>Outcome scores: KOOS</title><sec id="Sec13"><title>KOOS pain</title><p id="Par24">The clinical outcomes for the KOOS sub-scores for all studies are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. For the KOOS pain sub-score, five studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at baseline. The pooled estimate demonstrated significant differences in favor of the control group (SMD 0.230, 95% CI 0.033 to 0.426, <italic>p</italic>&#x02009;=&#x02009;0.02, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;5%; Supplementary Fig.&#x000a0;5). Although the SMD favored MSC at baseline, the magnitude of effect was small, suggesting that the differences were not relevant [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par25">For the KOOS pain sub-score, four studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at 3&#x000a0;months. The pooled estimate demonstrated non-significant between group differences but favored MSC (SMD &#x02212;&#x02009;0.592, 95% CI &#x02212;&#x02009;1.467 to 0.283 <italic>p</italic>&#x02009;=&#x02009;0.185, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;42%; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Although the SMD favored MSC at 3&#x000a0;months baseline, the magnitude of effect was small, suggesting that the differences were not relevant [<xref ref-type="bibr" rid="CR13">13</xref>].<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Forest Plot comparing the KOOS subscale pain at 3&#x000a0;months demonstrated non-significant between group differences in favor of the control group (<italic>p</italic>&#x02009;=&#x02009;0.185)</p></caption><graphic xlink:href="590_2025_4322_Fig3_HTML" id="MO3"/></fig></p><p id="Par26">For the KOOS pain sub-score, four studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at 6&#x000a0;months. The pooled estimate demonstrated near significant between group differences in favor of MSC (SMD &#x02212;&#x02009;0.543, 95% CI &#x02212;&#x02009;1.087 to 0.001, <italic>p</italic>&#x02009;=&#x02009;0.051, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;42%; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). The magnitude of effect was moderate, suggesting that the differences were relevant [<xref ref-type="bibr" rid="CR13">13</xref>].<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Forest Plot comparing the KOOS subscale pain at 6&#x000a0;months demonstrated near significant between group differences in favor of MSCs (<italic>p</italic>&#x02009;=&#x02009;0.051)</p></caption><graphic xlink:href="590_2025_4322_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec14"><title>KOOS symptoms</title><p id="Par27">For the KOOS symptoms sub-score, five studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at baseline. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.330, 95% CI &#x02212;&#x02009;0.685 to 0.026, <italic>p</italic>&#x02009;=&#x02009;0.069, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;61%; Supplementary Fig.&#x000a0;6).</p><p id="Par28">For the KOOS symptoms sub-score, four studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at 3&#x000a0;months. The pooled estimate demonstrated significant between group differences in favor of MSC (SMD &#x02212;&#x02009;0.835, 95% CI &#x02212;&#x02009;1.594 to &#x02212;&#x02009;0.076, <italic>p</italic>&#x02009;=&#x02009;0.031, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;512%; Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). The magnitude of effect was large, suggesting that the differences were relevant.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Forest Plot comparing the KOOS subscale symptoms at 3&#x000a0;months demonstrated significant between group differences in favor of MSCs (<italic>p</italic>&#x02009;=&#x02009;0.031)</p></caption><graphic xlink:href="590_2025_4322_Fig5_HTML" id="MO5"/></fig></p><p id="Par29">For the KOOS symptoms sub-score, four studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at 6&#x000a0;months. The pooled estimate demonstrated significant between group differences in favor of MSC (SMD &#x02212;&#x02009;0.848, 95% CI &#x02212;&#x02009;1.677 to &#x02212;&#x02009;0.019, <italic>p</italic>&#x02009;=&#x02009;0.045, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;47%; Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). The magnitude of effect was large, suggesting that the differences were relevant.<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Forest Plot comparing the KOOS subscale symptoms at 6&#x000a0;months demonstrated significant between group differences in favor of MSCs (<italic>p</italic>&#x02009;=&#x02009;0.045)</p></caption><graphic xlink:href="590_2025_4322_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec15"><title>KOOS ADL</title><p id="Par30">For the KOOS ADL sub-score, five studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at baseline. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.122, 95% CI &#x02212;&#x02009;0.487 to 0.243, <italic>p</italic>&#x02009;=&#x02009;0.511, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;56%; Supplementary Fig.&#x000a0;7).</p><p id="Par31">For the KOOS ADL sub-score, four studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at 3&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.238, 95% CI &#x02212;&#x02009;0.709 to 0.232, <italic>p</italic>&#x02009;=&#x02009;0.321, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;68%; (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>).<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>Forest Plot comparing the KOOS subscale ADL at 3&#x000a0;months could not demonstrate significant between group differences (<italic>p</italic>&#x02009;=&#x02009;0.321)</p></caption><graphic xlink:href="590_2025_4322_Fig7_HTML" id="MO7"/></fig></p><p id="Par32">For the KOOS ADL sub-score, four studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at 6&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.308, 95% CI &#x02212;&#x02009;0.919 to 0.304, <italic>p</italic>&#x02009;=&#x02009;0.324, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;81%; Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>).<fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p>Forest Plot comparing the KOOS subscale ADL at 6&#x000a0;months could not demonstrate significant between group differences (<italic>p</italic>&#x02009;=&#x02009;0.324)</p></caption><graphic xlink:href="590_2025_4322_Fig8_HTML" id="MO8"/></fig></p></sec><sec id="Sec16"><title>KOOS sports</title><p id="Par33">For the KOOS sub-score sports, five studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at baseline. The pooled estimate did not demonstrate significant between group differences (SMD 0.278, 95% CI &#x02212;&#x02009;0.245 to 0.800, <italic>p</italic>&#x02009;=&#x02009;0.298, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;78%; Supplementary Fig.&#x000a0;8).</p><p id="Par34">For the KOOS sub-score sports, four studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at 3&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.883, 95% CI &#x02212;&#x02009;2.014 to 0.248, <italic>p</italic>&#x02009;=&#x02009;0.126, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;94%; Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>).<fig id="Fig9"><label>Fig.&#x000a0;9</label><caption><p>Forest Plot comparing the KOOS subscale sports at 3&#x000a0;months could not demonstrate significant between group differences (<italic>p</italic>&#x02009;=&#x02009;0.126)</p></caption><graphic xlink:href="590_2025_4322_Fig9_HTML" id="MO9"/></fig></p><p id="Par35">For the KOOS sub-score sports, four studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at 6&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.315, 95% CI &#x02212;&#x02009;1.496 to 0.867, <italic>p</italic>&#x02009;=&#x02009;0.602, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;94%; (Fig.&#x000a0;<xref rid="Fig10" ref-type="fig">10</xref>).<fig id="Fig10"><label>Fig.&#x000a0;10</label><caption><p>Forest Plot comparing the KOOS subscale sports at 6&#x000a0;months could not demonstrate significant between group differences (<italic>p</italic>&#x02009;=&#x02009;0.602)</p></caption><graphic xlink:href="590_2025_4322_Fig10_HTML" id="MO10"/></fig></p></sec><sec id="Sec17"><title>KOOS quality of life</title><p id="Par36">For the KOOS QOL sub-score, five studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at baseline. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.182, 95% CI &#x02212;&#x02009;0.506 to 0.142, <italic>p</italic>&#x02009;=&#x02009;0.272, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;46%; Supplementary Fig.&#x000a0;9).</p><p id="Par37">For the KOOS QOL sub-score at 3&#x000a0;months, four studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at 3&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.495, 95% CI &#x02212;&#x02009;1.098 to 0.109, <italic>p</italic>&#x02009;=&#x02009;0.108, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;81%; Fig.&#x000a0;<xref rid="Fig11" ref-type="fig">11</xref>).<fig id="Fig11"><label>Fig.&#x000a0;11</label><caption><p>Forest Plot comparing the KOOS subscale QOL at 3&#x000a0;months could not demonstrate significant between group differences (<italic>p</italic>&#x02009;=&#x02009;0.108)</p></caption><graphic xlink:href="590_2025_4322_Fig11_HTML" id="MO11"/></fig></p><p id="Par38">For the KOOS QOL sub-score, four studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] were included for analysis at 6&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;1.112, 95% CI &#x02212;&#x02009;2.363 to 0.140, <italic>p</italic>&#x02009;=&#x02009;0.082, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;95%; (Fig.&#x000a0;<xref rid="Fig12" ref-type="fig">12</xref>).<fig id="Fig12"><label>Fig.&#x000a0;12</label><caption><p>Forest Plot comparing the KOOS subscale QOL at 12&#x000a0;months could not demonstrate significant between group differences (<italic>p</italic>&#x02009;=&#x02009;0.082)</p></caption><graphic xlink:href="590_2025_4322_Fig12_HTML" id="MO12"/></fig></p></sec></sec><sec id="Sec18"><title>Outcome scores: WOMAC</title><sec id="Sec19"><title>WOMAC total</title><p id="Par39">For the WOMAC total score, seven studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] were included for analysis at baseline. The pooled estimate did not demonstrate significant between group differences (SMD 0.119, 95% CI &#x02212;&#x02009;0.069 to 0.307, <italic>p</italic>&#x02009;=&#x02009;0.215, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%; Supplementary Fig.&#x000a0;10).</p><p id="Par40">For the WOMAC total score, six studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] were included for analysis at 3&#x000a0;months. The pooled estimate demonstrated significant between group differences in favour of MSC. (SMD &#x02212;&#x02009;0.514, 95% CI &#x02212;&#x02009;1.005 to &#x02212;&#x02009;0.023, <italic>p</italic>&#x02009;=&#x02009;0.040, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;78%; Fig.&#x000a0;<xref rid="Fig13" ref-type="fig">13</xref>). The magnitude of effect was medium, suggesting that the differences were relevant.<fig id="Fig13"><label>Fig.&#x000a0;13</label><caption><p>Forest Plot comparing the total WOMAC score at 3&#x000a0;months demonstrated significant between group differences in favor of MSCs (<italic>p</italic>&#x02009;=&#x02009;0.04)</p></caption><graphic xlink:href="590_2025_4322_Fig13_HTML" id="MO13"/></fig></p><p id="Par41">For the WOMAC total score, seven studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] were included for analysis at 6&#x000a0;months. The pooled estimate reached near significance between groups in favour of MSC. (SMD &#x02212;&#x02009;0.608, 95% CI &#x02212;&#x02009;1.275 to 0.060, <italic>p</italic>&#x02009;=&#x02009;0.074, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;96%; Fig.&#x000a0;<xref rid="Fig14" ref-type="fig">14</xref>). The magnitude of effect was medium, suggesting that the differences were relevant.<fig id="Fig14"><label>Fig.&#x000a0;14</label><caption><p>Forest Plot comparing the total WOMAC score at 6&#x000a0;months demonstrated near significant between group differences in favor of MSCs (<italic>p</italic>&#x02009;=&#x02009;0.074)</p></caption><graphic xlink:href="590_2025_4322_Fig14_HTML" id="MO14"/></fig></p><p id="Par42">For the WOMAC total score, five studies [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>] were included for analysis at 12&#x000a0;months. The pooled estimate did not demonstrate between group differences (SMD &#x02212;&#x02009;0.537, 95% CI &#x02212;&#x02009;1.460 to 0.385, <italic>p</italic>&#x02009;=&#x02009;0.253, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;86%; Fig.&#x000a0;<xref rid="Fig15" ref-type="fig">15</xref>).<fig id="Fig15"><label>Fig.&#x000a0;15</label><caption><p>Forest Plot comparing the total WOMAC score at 12&#x000a0;months did not demonstrate significant between group differences (<italic>p</italic>&#x02009;=&#x02009;0.253)</p></caption><graphic xlink:href="590_2025_4322_Fig15_HTML" id="MO15"/></fig></p></sec><sec id="Sec20"><title>WOMAC pain</title><p id="Par43">For the WOMAC pain score, six studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] were included for analysis at baseline. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.430, 95% CI &#x02212;&#x02009;1.043 to 0.183, <italic>p</italic>&#x02009;=&#x02009;0.169, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;84%; Supplementary Fig.&#x000a0;11).</p><p id="Par44">For the WOMAC pain score, four studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] were included for analysis at 3&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.314, 95% CI &#x02212;&#x02009;1.124 to 0.496, <italic>p</italic>&#x02009;=&#x02009;0.448, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;49%; Supplementary Fig.&#x000a0;12).</p><p id="Par45">For the WOMAC pain score, six studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] were included for analysis at 6&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.443, 95% CI &#x02212;&#x02009;1.065 to 0.178 <italic>p</italic>&#x02009;=&#x02009;0.162, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;80%; Supplementary 13).</p><p id="Par46">For the WOMAC pain score, four studies [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>] were included for analysis at 12&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.305, 95% CI &#x02212;&#x02009;0.776 to 0.165 <italic>p</italic>&#x02009;=&#x02009;0.204, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;49%; Supplementary Fig.&#x000a0;14).</p></sec><sec id="Sec21"><title>WOMAC stiffness</title><p id="Par47">For the WOMAC stiffness score, six studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] were included for analysis at baseline. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.155, 95% CI &#x02212;&#x02009;0.5333 to 0.040, <italic>p</italic>&#x02009;=&#x02009;0.119, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%; Supplementary Fig.&#x000a0;15).</p><p id="Par48">For the WOMAC stiffness score, five studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>] were included for analysis at 3&#x000a0;months. The pooled estimate reached near significance in favour of MSC (SMD &#x02212;&#x02009;0.192, 95% CI &#x02212;&#x02009;0.402 to 0.017 <italic>p</italic>&#x02009;=&#x02009;0.072, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%; Supplementary Fig.&#x000a0;16).</p><p id="Par49">For the WOMAC stiffness score, six studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] were included for analysis at 6&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.104, 95% CI &#x02212;&#x02009;0.596 to 0.388, <italic>p</italic>&#x02009;=&#x02009;0.678, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%; Supplementary Fig.&#x000a0;17).</p><p id="Par50">For the WOMAC stiffness score, four studies [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] were included for analysis at 12&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD 0.067, 95% CI &#x02212;&#x02009;0.655 to 0.789, <italic>p</italic>&#x02009;=&#x02009;0.856, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;32%; Supplementary Fig.&#x000a0;18).</p></sec><sec id="Sec22"><title>WOMAC function</title><p id="Par51">For the WOMAC function score, six studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] were included for analysis at baseline. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.173, 95% CI &#x02212;&#x02009;0.369 to 0.022 <italic>p</italic>&#x02009;=&#x02009;0.082, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;15%; Supplementary Fig.&#x000a0;19).</p><p id="Par52">For the WOMAC function score, six studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] were included for analysis at 3&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD 0.012, 95% CI &#x02212;&#x02009;0.341 to 0.365 <italic>p</italic>&#x02009;=&#x02009;0.946, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;50%; Supplementary Fig.&#x000a0;20).</p><p id="Par53">For the WOMAC function score, six studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] were included for analysis at 6&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD &#x02212;&#x02009;0.632, 95% CI &#x02212;&#x02009;1.411 to 0.146 <italic>p</italic>&#x02009;=&#x02009;0.112, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;89%; Supplementary Fig.&#x000a0;21).</p><p id="Par54">For the WOMAC function score, four studies [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>] were included for analysis at 12&#x000a0;months. The pooled estimate did not demonstrate significant between group differences (SMD 0.117, 95% CI &#x02212;&#x02009;0.214 to 0.448; <italic>p</italic>&#x02009;=&#x02009;0.488, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;0%; Supplementary Fig.&#x000a0;22).</p></sec></sec></sec><sec id="Sec23"><title>Discussion</title><p id="Par55">The results of this meta-analysis demonstrated a significant effect of adipose and bone marrow-derived stromal cell (MSC) injections on pain reduction, as measured by the Visual Analog Scale (VAS) for pain, at all assessed time points. Furthermore, MSC injections showed superiority over other non-surgical treatment options. However, these significant differences were not observed in the pain subscales of the Knee injury and Osteoarthritis Outcome Score (KOOS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Only the KOOS pain subscale corroborated the findings of the VAS pain score, demonstrating significantly reduced symptoms in the MSC group. In addition, the lower pain scores were not associated with any clinical differences. This conclusion is based on the analysis of KOOS subscores (ADL, Sport, and QoL) and WOMAC subscores (Stiffness and Function), which reflect functional outcomes. None of the comparisons demonstrated statistically significant differences, suggesting that MSC injection therapy does not result in functional improvement.</p><p id="Par56">Quality assessment of the included studies, using both the GRADE approach and CMS score, indicated that 80% were of high or moderate quality. Additionally, 70% of the studies were assessed as having a low risk of bias, supporting the conclusion that the overall risk of bias across the included studies was low. According to the Cochrane Handbook, the confidence in the effect estimate can be classified as moderate to high. This suggests that the true effect is likely to be close to the estimated effect, indicating a high probability that the study results are clinically relevant.</p><p id="Par57">Several other meta-analyses reporting on the use of adipose-derived mesenchymal stem cells (ADMSCs) and bone marrow-derived mesenchymal stem cells (BMSCs) for the conservative treatment of knee osteoarthritis have been published over the past five years [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Of these seven studies, only one, by Dai et al. [<xref ref-type="bibr" rid="CR31">31</xref>], did not demonstrate significant differences favouring mesenchymal stromal cells over other injection therapy modalities.</p><p id="Par58">Kim et al. [<xref ref-type="bibr" rid="CR10">10</xref>] included five studies published between 2013 and 2020, demonstrating an improvement in the WOMAC score. However, their analysis is limited by potential selection bias due to the inclusion of both autologous and allogeneic cells. Han et al. [<xref ref-type="bibr" rid="CR32">32</xref>] included nine studies published between 2013 and 2019 and reported the superiority of mesenchymal stromal cells for the VAS but not the WOMAC score, with limitations arising from the inclusion of both autologous and allogeneic cells. Agarwal et al. [<xref ref-type="bibr" rid="CR33">33</xref>] included 18 studies published between 2013 and 2020, showing significant differences favouring mesenchymal stromal cells in the WOMAC score. This study is severely limited by bias due to the inclusion of studies that also used arthroscopic intervention and stromal vascular fraction injections. Issa et al. [<xref ref-type="bibr" rid="CR34">34</xref>] included only four studies, all published in 2019, and showed an improvement in the WOMAC score in favour of mesenchymal stromal cells. The included studies used only autologous mesenchymal cells, resulting in the lowest heterogeneity regarding the injected material among these meta-analyses. Kim et al. [<xref ref-type="bibr" rid="CR10">10</xref>] included five studies published between 2019 and 2020, reporting an advantage of mesenchymal cells but no significant between-group differences. Their study is also limited by additional surgical interventions in three studies and the use of stromal vascular fraction in two studies. Finally, Muthu et al. [<xref ref-type="bibr" rid="CR35">35</xref>] included 21 studies published between 2002 and 2020, showing that MSCs are superior to other interventions, resulting in less pain and better function. However, the authors included studies with additional surgical interventions, allogeneic cells, and stromal vascular fraction, which limits the conclusions drawn.</p><p id="Par59">Dai et al. [<xref ref-type="bibr" rid="CR31">31</xref>] included 13 studies published between 2015 and 2020 and could not demonstrate any differences between the intervention and control groups. Unfortunately, they also included studies applying allogeneic mesenchymal stromal cells. Interestingly, Dai et al. [<xref ref-type="bibr" rid="CR31">31</xref>] demonstrated significant differences in favor of mesenchymal stromal cells (MSCs) for pain and WOMAC scores when compared to a control group or a control group using hyaluronic acid. However, they could not demonstrate significant differences in pain scores when comparing MSCs to a placebo. Therefore, one could argue that their study [<xref ref-type="bibr" rid="CR31">31</xref>] also supports the use of MSC injections compared to other treatment modalities. The authors utilized the Minimal Clinically Important Difference (MCID) as a differentiator to assess the effect of the injections. They argued that despite achieving statistical significance, the differences did not reach the MCID threshold, indicating that the observed changes may not be clinically meaningful.</p><p id="Par60">To minimize bias and enhance the validity of our findings, we have exclusively included studies that compared autologous and cultured adipose-derived and bone marrow-derived stromal cells with other orthobiologic interventions and injection therapies. Additionally, we have excluded studies older than ten years due to the rapid advancements in this field. The volume of publications has increased exponentially over the past decade, reflecting the swift progress in research and development [<xref ref-type="bibr" rid="CR36">36</xref>]. Seventy percent of the included studies exhibited a low risk of bias, while two studies were categorized as high risk primarily due to confounding factors. The GRADE quality assessment resulted in an overall high to moderate level of certainty, suggesting that the confidence in the effect estimate is close to the true effect. Furthermore, the study quality assessment using the CMS score indicated that 70% of the studies were of high or good quality. Therefore, one can cautiously conclude that the results of this meta-analysis are both valid and clinically relevant. This conclusion is supported by the observation that study quality was primarily reduced due to a relatively short mean follow-up period of less than three years and insufficient description of post-intervention rehabilitation protocols. However, these variables may be less critical since a long-lasting effect of injections on symptom reduction in patients with knee osteoarthritis may not be anticipated. Many clinical studies are limited by small sample sizes, which may lead to Type II errors and undermine the validity of their findings. Katz et al. demonstrated that a minimum sample size of 172 patients is necessary to achieve a power of 0.9 [<xref ref-type="bibr" rid="CR37">37</xref>]. This meta-analysis, which includes a total of 563 patients, enhances the statistical power and supports the potential clinical efficacy of mesenchymal stromal cells (MSCs) in alleviating pain in individuals with knee osteoarthritis.</p><p id="Par61">Osteoarthritis is characterized by the irreversible degeneration of articular cartilage, which often results in significant functional impairment [<xref ref-type="bibr" rid="CR38">38</xref>]. When conservative treatments fail, total knee arthroplasty becomes the primary surgical intervention [<xref ref-type="bibr" rid="CR39">39</xref>]. In recent years, orthobiologics have emerged as promising alternatives, offering potential benefits such as pain reduction, functional enhancement, and the possibility for tissue repair and regeneration. Among these therapies, cell-based therapy with either adipose or bone marrow-derived stromal cells have shown promise in alleviating symptoms and improving both functional capacity and overall quality of life [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par62">Initially, it was thought that the therapeutic effects of mesenchymal stem cells (MSCs) were primarily due to their ability to migrate and engraft in targeted tissues [<xref ref-type="bibr" rid="CR41">41</xref>]. However, subsequent research has demonstrated that the beneficial outcomes of MSCs are largely attributable to their secretion of trophic factors [<xref ref-type="bibr" rid="CR41">41</xref>]. These factors play a crucial role in mediating cell-to-cell communication, regulating cell proliferation and differentiation, and exerting anti-inflammatory effects [<xref ref-type="bibr" rid="CR41">41</xref>]. The paracrine effects of mesenchymal stromal cells (MSCs) reducing inflammatory responses may therefore be the primary mechanism of action contributing to the observed reduction in pain and improvement in function following MSC injections into the knee [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par63">The results of this meta-analysis should be considered within the context of several limitations. The potential influence of missed studies cannot be ruled out, despite the use of comprehensive search strategies. These strategies were, however, restricted to publications in English and German, which may have resulted in the omission of high-quality evidence published in other languages. Unfortunately, the presence of publication bias was confirmed, which may be attributable to the exclusion of search strategies in other languages, particularly Chinese. We excluded one study published in Chinese, which suggests that other relevant studies may have been overlooked. Additionally, the asymmetry of the funnel plot and the significant result from Egger's test may partly be explained by the heterogeneity of the included studies, which could suggest that some effect sizes in the comparative analyses may be slightly overestimated. However, if overestimation is assumed, it would imply that MSC injection therapy may not be as effective for pain and further strengthening the conclusion that MSCs have no effect on clinical outcomes and function, as suggested by this study. The included studies were heterogeneous with respect to the source of cells used. Five studies employed bone marrow-derived stem cells (BMSCs), while five studies used adipose-derived stem cells (ADSCs). This variation in cell source may have influenced the results. Han et al. [<xref ref-type="bibr" rid="CR32">32</xref>] suggested that ADSCs might be superior; however, their analysis reported a mean difference (MD) of 1.64 for BMSCs and 1.85 for ADSCs at six months, with similar MDs observed at twelve months. Despite the statistical significance of these findings, the clinical relevance of the treatment effects may therefore be limited. The dosage of injected mesenchymal stromal cells (MSCs) varied across studies, with some studies not specifying the dosages used. It is possible that higher doses of MSCs may have led to improved outcomes. Additionally, the control groups were heterogeneous, encompassing various treatment options, which could have introduced bias and potentially skewed the results in either direction. Other meta-analysis techniques, such as subgroup analysis, meta-regression, and sensitivity analysis, offer valuable methods for exploring potential sources of heterogeneity. However, these approaches require more than ten studies to yield reliable and valid results; without this threshold, their findings may be unstable or misleading. Unfortunately, our study was not sufficiently powered to apply these methods without introducing potential bias. Consequently, it is possible that the inclusion of additional studies could alter the treatment effect in either direction.</p></sec><sec id="Sec24"><title>Conclusions</title><p id="Par64">The results of this meta-analysis demonstrated a significant effect of adipose and bone marrow-derived stromal cell (MSC) injections on pain reduction at all assessed time points, and MSC injections showed superiority over other non-surgical treatment options. These differences were not reflected in clinical and functional outcomes, indicating that the observed reduction in pain did not correspond to substantial improvements in knee functionality.</p></sec><sec id="Sec25" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="590_2025_4322_MOESM1_ESM.tif"><caption><p><bold>Supplementary Figure 1:</bold> PRISMA Flow Diagram. From the initial 1576 records, 10 studies were included in the quantitative synthesis. (TIF 66 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="590_2025_4322_MOESM2_ESM.tif"><caption><p><bold>Supplementary Figure 2:</bold> The funnel plot exhibited asymmetry in the standard deviations of the means, suggesting the presence of publication bias. (TIF 45 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="590_2025_4322_MOESM3_ESM.tif"><caption><p><bold>Supplementary Figure 3:</bold> The Forest Plot did not demonstrate significant between group differences at baseline. (TIF 35 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="590_2025_4322_MOESM4_ESM.tif"><caption><p><bold>Supplementary Figure 4:</bold> Forest Plot comparing VAS at 12 months demonstrated between group significant differences (p=0.001) in favor of MSCs. (TIF 28 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="590_2025_4322_MOESM5_ESM.tif"><caption><p><bold>Supplementary Figure 5:</bold> Forest Plot comparing the KOOS subscale pain at baseline demonstrated significant between group differences in favor of the control group (p=0.02) (TIF 26 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="590_2025_4322_MOESM6_ESM.tif"><caption><p><bold>Supplementary Figure 6:</bold> Forest Plot comparing the KOOS subscale symptoms at baseline did not demonstrate significant between group differences. (p=0.069) (TIF 29 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="590_2025_4322_MOESM7_ESM.tif"><caption><p><bold>Supplementary Figure 7:</bold> Forest Plot comparing the KOOS subscale ADL at baseline could not demonstrate significant between group differences (p=0.511) (TIF 29 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="590_2025_4322_MOESM8_ESM.docx"><caption><p><bold>Supplementary Figure 8:</bold> Forest Plot comparing the KOOS subscale sports at baseline could not demonstrate significant between group differences (p=0.298) (DOCX 34 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="590_2025_4322_MOESM9_ESM.tif"><caption><p><bold>Supplementary Figure 9:</bold> Forest Plot comparing the KOOS subscale QOL at baseline could not demonstrate significant between group differences (p=0.272) (TIF 47 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM10"><media xlink:href="590_2025_4322_MOESM10_ESM.tif"><caption><p><bold>Supplementary Figure 10:</bold> Forest Plot comparing the total WOMAC score at baseline could not demonstrate significant between group differences (p=0.215) (TIF 32 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM11"><media xlink:href="590_2025_4322_MOESM11_ESM.tif"><caption><p><bold>Supplementary Figure 11:</bold> Forest Plot comparing the WOMAC subscore pain at baseline did not demonstrate significant between group differences (p=0.169) (TIF 59 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM12"><media xlink:href="590_2025_4322_MOESM12_ESM.tif"><caption><p><bold>Supplementary Figure 12:</bold> Forest Plot comparing the WOMAC subscore pain at 3 months did not demonstrate significant between group differences (p=0.448) (TIF 53 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM13"><media xlink:href="590_2025_4322_MOESM13_ESM.docx"><caption><p><bold>Supplementary Figure 13:</bold> Forest Plot comparing the WOMAC sub-score pain at 6 months did not demonstrate significant between group differences (p=0.162) (DOCX 158 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM14"><media xlink:href="590_2025_4322_MOESM14_ESM.docx"><caption><p><bold>Supplementary Figure 14:</bold> Forest Plot comparing the WOMAC subscore pain at 12 months did not demonstrate significant between group differences (p=0.204) (DOCX 134 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM15"><media xlink:href="590_2025_4322_MOESM15_ESM.tif"><caption><p><bold>Supplementary Figure 15:</bold> Forest Plot comparing the WOMAC subscore stiffness at baseline did not demonstrate significant between group differences (p=0.119) (TIF 154 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM16"><media xlink:href="590_2025_4322_MOESM16_ESM.tif"><caption><p><bold>Supplementary Figure 16:</bold> Forest Plot comparing the WOMAC subscore stiffness at 3 months demonstrated near significant between group differences in favor of MSCs (p=0.072) (TIF 54 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM17"><media xlink:href="590_2025_4322_MOESM17_ESM.tif"><caption><p><bold>Supplementary Figure 17:</bold> Forest Plot comparing the WOMAC subscore stiffness at 6 months did not demonstrate significant between group differences (p=0.678) (TIF 62 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM18"><media xlink:href="590_2025_4322_MOESM18_ESM.tif"><caption><p><bold>Supplementary Figure 18:</bold> Forest Plot comparing the WOMAC subscore stiffness at 12 months did not demonstrate significant between group differences (p=0.856) (TIF 54 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM19"><media xlink:href="590_2025_4322_MOESM19_ESM.tif"><caption><p><bold>Supplementary Figure 19:</bold> Forest Plot comparing the WOMAC subscore function at baseline did not demonstrate significant between group differences (p=0.082) (TIF 57 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM20"><media xlink:href="590_2025_4322_MOESM20_ESM.tif"><caption><p><bold>Supplementary Figure 20:</bold> Forest Plot comparing the WOMAC subscore function at 3 months did not demonstrate significant between group differences (p=0.946) (TIF 59 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM21"><media xlink:href="590_2025_4322_MOESM21_ESM.tif"><caption><p><bold>Supplementary Figure 21:</bold> Forest Plot comparing the WOMAC subscore function at 6 months did not demonstrate significant between group differences (p=0.112) (TIF 59 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM22"><media xlink:href="590_2025_4322_MOESM22_ESM.tif"><caption><p><bold>Supplementary Figure 22:</bold> Forest Plot comparing the WOMAC subscore function at 12 months did not demonstrate significant between group differences (p=0.488) (TIF 49 kb)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Erik Hohmann: 1.made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; 2.drafted the work or revised it critically for important intellectual content; 3. approved the version to be published; and 4.agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Natalie Keough: 1.made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; 2. drafted the work or revised it critically for important intellectual content; 3. approved the version to be published; and 4. agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Daniel Stokes: 1.made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; 2. drafted the work or revised it critically for important intellectual content; 3. approved the version to be published; and 4. agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Rachel M Frank: 1. made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; 2. drafted the work or revised it critically for important intellectual content; 3. approved the version to be published; and 4.agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Scott Rodeo: 1. made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; 2. drafted the work or revised it critically for important intellectual content; 3. approved the version to be published; and 4. agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by University of Pretoria. This study did not receive any funding. [<xref ref-type="bibr" rid="CR1">1</xref>] None of the authors have received any funding or sponsorship for this study, including funds or materials (e.g., surgical supplies, specimens)?. [<xref ref-type="bibr" rid="CR2">2</xref>] The following authors have in the past five years, received the following from an organization that may in any way gain or lose financially from the results of your study: RF: none (consulting/speaking fees: Allosource, Arthrex, JF Ortho; royalties: Elsevier; research support: Arthrex, Aesculap), SR: none (research funds: OREF, NIH, Virginia Toulmin Foundation). [<xref ref-type="bibr" rid="CR3">3</xref>] None of the authors Have, in the past five years, been employed by or on the Board of an organization that may in any way gain or lose financially from the results of your study?. [<xref ref-type="bibr" rid="CR4">4</xref>] The following authors hold any stocks or bonds in an organization that may in any way gain or lose financially from the results of your study? SR: no (stocks: Jannu Therapeutics, Overture). [<xref ref-type="bibr" rid="CR5">5</xref>] None of the authors are affiliated, currently hold any patents that are relevant to the study in any way, or are you currently applying for or planning to apply for such a patent?. [<xref ref-type="bibr" rid="CR6">6</xref>] The following authors have any other potential financial conflict of interest: RF: Consulting/speaking fees: Allosource, Arthrex, JF Ortho; royalties: Elsevier; research support: Arthrex, Aesculap; SR: Consulting Fees Teladoc Health, Don Joy. [<xref ref-type="bibr" rid="CR7">7</xref>] The following authors have any affiliation with any commercial entity or organization not related to this particular study, but related to orthopaedic surgery or another branch of medicine: EH: Yes, Editorial Board Arthroscopy Journal, The Hive-Musculoskeletal Journal, Beemed; SR: Editor Translational Medicine, Am J Sports Medicine. [<xref ref-type="bibr" rid="CR8">8</xref>] None of the authors have any non-reimbursed relationships that may be seen as a conflict of interest?</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par65">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Kolasinski</surname><given-names>SL</given-names></name><name><surname>Neogi</surname><given-names>T</given-names></name><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Oatis</surname><given-names>C</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Block</surname><given-names>J</given-names></name><etal/></person-group><article-title>American college of rheumatology/arthritis foundation guidelines for the management of osteoarthritis of the hand, hip and knee</article-title><source>Arthritis Care Res (Hoboken)</source><year>2019</year><volume>72</volume><issue>2</issue><fpage>149</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1002/acr.24131</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J et al (2019) American college of rheumatology/arthritis foundation guidelines for the management of osteoarthritis of the hand, hip and knee. Arthritis Care Res (Hoboken) 72(2):149&#x02013;162. 10.1002/acr.24131</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Bannuru</surname><given-names>RR</given-names></name><name><surname>Osani</surname><given-names>MC</given-names></name><name><surname>Vaysbrot</surname><given-names>EE</given-names></name><name><surname>Arden</surname><given-names>NK</given-names></name><name><surname>Bennell</surname><given-names>K</given-names></name><name><surname>Biema-Zeinstra</surname><given-names>SMA</given-names></name><etal/></person-group><article-title>OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis</article-title><source>Osteoarthr Cartil</source><year>2019</year><volume>27</volume><issue>11</issue><fpage>1578</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2019.06.011</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Biema-Zeinstra SMA et al (2019) OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil 27(11):1578&#x02013;1589. 10.1016/j.joca.2019.06.011</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Couldrick</surname><given-names>JM</given-names></name><name><surname>Woodward</surname><given-names>AP</given-names></name><name><surname>Silva</surname><given-names>MDC</given-names></name><name><surname>Lynch</surname><given-names>JT</given-names></name><name><surname>Perriman</surname><given-names>DM</given-names></name><name><surname>Barton</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Evidence for key individual characteristics associated with outcomes following combined first-line interventions for knee osteoarthritis: a systematic review</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><issue>4</issue><fpage>e0284249</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0284249</pub-id><pub-id pub-id-type="pmid">37040393</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Couldrick JM, Woodward AP, Silva MDC, Lynch JT, Perriman DM, Barton CJ et al (2023) Evidence for key individual characteristics associated with outcomes following combined first-line interventions for knee osteoarthritis: a systematic review. PLoS ONE 18(4):e0284249. 10.1371/journal.pone.0284249<pub-id pub-id-type="pmid">37040393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Mavrogenis</surname><given-names>AF</given-names></name><name><surname>Karampikas</surname><given-names>V</given-names></name><name><surname>Zikopoulos</surname><given-names>A</given-names></name><name><surname>Sioutis</surname><given-names>S</given-names></name><name><surname>Mastrakalos</surname><given-names>D</given-names></name><name><surname>Koulalis</surname><given-names>D</given-names></name><etal/></person-group><article-title>Orthobiologics: a review</article-title><source>Int Orthop</source><year>2023</year><volume>47</volume><issue>7</issue><fpage>1645</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.1007/s00264-023-05803-z</pub-id><pub-id pub-id-type="pmid">37071148</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Mavrogenis AF, Karampikas V, Zikopoulos A, Sioutis S, Mastrakalos D, Koulalis D et al (2023) Orthobiologics: a review. Int Orthop 47(7):1645&#x02013;1662. 10.1007/s00264-023-05803-z<pub-id pub-id-type="pmid">37071148</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Merchan</surname><given-names>EC</given-names></name></person-group><article-title>Intraarticular injections of mesenchymal stem cells in knee osteoarthritis: a review of their current molecular mechanisms of action and their efficacy</article-title><source>Int J Mol Sci</source><year>2022</year><volume>29</volume><issue>23</issue><fpage>14953</fpage><pub-id pub-id-type="doi">10.3390/ijms232314953</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Rodriguez-Merchan EC (2022) Intraarticular injections of mesenchymal stem cells in knee osteoarthritis: a review of their current molecular mechanisms of action and their efficacy. Int J Mol Sci 29(23):14953. 10.3390/ijms232314953</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>R</given-names></name></person-group><article-title>Unproven but profitable: the boom in US stem cell clinics</article-title><source>JAMA</source><year>2018</year><volume>320</volume><issue>14</issue><fpage>1421</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.1001/jama.2018.13861</pub-id><pub-id pub-id-type="pmid">30326510</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Rubin R (2018) Unproven but profitable: the boom in US stem cell clinics. JAMA 320(14):1421&#x02013;1423. 10.1001/jama.2018.13861<pub-id pub-id-type="pmid">30326510</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>Z</given-names></name><name><surname>Waynan</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>A systematic review, umbrella review and quality assessment on clinical translation of stem cell therapy for knee osteoarthritis: Are we there yet?</article-title><source>Stem Cell Res Ther</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>91</fpage><pub-id pub-id-type="doi">10.1186/s13287-023-03332-5</pub-id><pub-id pub-id-type="pmid">37061744</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Shang Z, Waynan P, Zhang B, Wang M, Wang X (2023) A systematic review, umbrella review and quality assessment on clinical translation of stem cell therapy for knee osteoarthritis: Are we there yet? Stem Cell Res Ther 14(1):91. 10.1186/s13287-023-03332-5<pub-id pub-id-type="pmid">37061744</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>SHS</given-names></name><name><surname>Kwan</surname><given-names>YT</given-names></name><name><surname>Neo</surname><given-names>WJ</given-names></name><name><surname>Jy</surname><given-names>C</given-names></name><name><surname>Kue</surname><given-names>TYJ</given-names></name><name><surname>See</surname><given-names>JZF</given-names></name><etal/></person-group><article-title>Intra-articular injections of mesenchymal stem cells without adjuvant therapies for knee osteoarthritis: a systematic review and meta-analysis</article-title><source>Am J Sports Med</source><year>2021</year><volume>49</volume><issue>11</issue><fpage>3113</fpage><lpage>3124</lpage><pub-id pub-id-type="doi">10.1177/0363546520981704</pub-id><pub-id pub-id-type="pmid">33471552</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Tan SHS, Kwan YT, Neo WJ, Jy C, Kue TYJ, See JZF et al (2021) Intra-articular injections of mesenchymal stem cells without adjuvant therapies for knee osteoarthritis: a systematic review and meta-analysis. Am J Sports Med 49(11):3113&#x02013;3124. 10.1177/0363546520981704<pub-id pub-id-type="pmid">33471552</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>MC</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Moon</surname><given-names>YW</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name></person-group><article-title>Clinical efficacy and safety of the intra-articular injection of autologous adipose-derived mesenchymal stem cells for knee osteoarthritis: a phase III, randomized, double-blind, placebo-control trial</article-title><source>Am J Sports Med</source><year>2023</year><volume>51</volume><issue>9</issue><fpage>2243</fpage><lpage>2253</lpage><pub-id pub-id-type="doi">10.1177/03635465231179223</pub-id><pub-id pub-id-type="pmid">37345256</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Kim K, Lee MC, Lee JH, Moon YW, Lee WS (2023) Clinical efficacy and safety of the intra-articular injection of autologous adipose-derived mesenchymal stem cells for knee osteoarthritis: a phase III, randomized, double-blind, placebo-control trial. Am J Sports Med 51(9):2243&#x02013;2253. 10.1177/03635465231179223<pub-id pub-id-type="pmid">37345256</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KII</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name></person-group><article-title>Intra-articular injection of autologous-adipose derived stem cells or stromal vascular fractions: are they effective for patients with knee osteoarthritis? A systematic review with meta-analysis of randomized controlled trials</article-title><source>Am J Sports Med</source><year>2023</year><volume>51</volume><issue>3</issue><fpage>837</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1177/03635465211053893</pub-id><pub-id pub-id-type="pmid">35019764</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Kim KII, Kim MS, Kim JH (2023) Intra-articular injection of autologous-adipose derived stem cells or stromal vascular fractions: are they effective for patients with knee osteoarthritis? A systematic review with meta-analysis of randomized controlled trials. Am J Sports Med 51(3):837&#x02013;848. 10.1177/03635465211053893<pub-id pub-id-type="pmid">35019764</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Lan</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effect of intra-knee injection of autologous adipose stem cells or mesenchymal vascular components on short-term outcomes in patients with knee osteoarthritis: an updated meta-analysis of randomized controlled trials</article-title><source>Arthritis Res Ther</source><year>2023</year><volume>25</volume><issue>1</issue><fpage>147</fpage><pub-id pub-id-type="doi">10.1186/s13075-023-03134-3</pub-id><pub-id pub-id-type="pmid">37563715</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Yang Y, Lan Z, Yan J, Tang Z, Zhou L, Jin D et al (2023) Effect of intra-knee injection of autologous adipose stem cells or mesenchymal vascular components on short-term outcomes in patients with knee osteoarthritis: an updated meta-analysis of randomized controlled trials. Arthritis Res Ther 25(1):147. 10.1186/s13075-023-03134-3<pub-id pub-id-type="pmid">37563715</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Shamseer</surname><given-names>L</given-names></name><name><surname>Clarke</surname><given-names>M</given-names></name><name><surname>Ghersi</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Petticrew</surname><given-names>M</given-names></name><etal/></person-group><article-title>Preferred reporting items for systematic reviews and meta-analysis protocols (PRISMA-P) 2015 statement</article-title><source>Syst Rev</source><year>2015</year><volume>4</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/2046-4053-4-1</pub-id><pub-id pub-id-type="pmid">25554246</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al (2015) Preferred reporting items for systematic reviews and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1. 10.1186/2046-4053-4-1<pub-id pub-id-type="pmid">25554246</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Cumpston</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Page</surname><given-names>MJ</given-names></name><name><surname>Chandler</surname><given-names>J</given-names></name><name><surname>Welch</surname><given-names>VA</given-names></name><name><surname>Higgins</surname><given-names>JPT</given-names></name><etal/></person-group><article-title>Updated guidance for trusted symptomatic reviews of the Cochrane handbook for systematic reviews of interventions</article-title><source>Cochrane Database Syst Rev</source><year>2019</year><volume>10</volume><fpage>ED000142</fpage><pub-id pub-id-type="doi">10.1002/14651858.ED000142</pub-id><pub-id pub-id-type="pmid">31643080</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JPT et al (2019) Updated guidance for trusted symptomatic reviews of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10:ED000142. 10.1002/14651858.ED000142<pub-id pub-id-type="pmid">31643080</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Beks</surname><given-names>RB</given-names></name><name><surname>Ochen</surname><given-names>Y</given-names></name><name><surname>Frima</surname><given-names>H</given-names></name><name><surname>Smeeing</surname><given-names>DPJ</given-names></name><name><surname>van der Meijden</surname><given-names>O</given-names></name><name><surname>Timmers</surname><given-names>TK</given-names></name><name><surname>van der Velde</surname><given-names>D</given-names></name><name><surname>van Heijl</surname><given-names>M</given-names></name><name><surname>Leenen</surname><given-names>LPH</given-names></name><name><surname>Groenwold</surname><given-names>RHH</given-names></name><name><surname>Houwert</surname><given-names>RM</given-names></name></person-group><article-title>Operative versus nonoperative treatment of proximal humerus fractures: a systematic review, meta-analysis, and comparison of observational and randomized controlled trials</article-title><source>J Shoulder Elbow Surg</source><year>2018</year><volume>27</volume><issue>8</issue><fpage>1526</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1016/j.jse.2018.03.009</pub-id><pub-id pub-id-type="pmid">29735376</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Beks RB, Ochen Y, Frima H, Smeeing DPJ, van der Meijden O, Timmers TK, van der Velde D, van Heijl M, Leenen LPH, Groenwold RHH, Houwert RM (2018) Operative versus nonoperative treatment of proximal humerus fractures: a systematic review, meta-analysis, and comparison of observational and randomized controlled trials. J Shoulder Elbow Surg 27(8):1526&#x02013;1534. 10.1016/j.jse.2018.03.009<pub-id pub-id-type="pmid">29735376</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Bun</surname><given-names>RS</given-names></name><name><surname>Scheer</surname><given-names>J</given-names></name><name><surname>Guillo</surname><given-names>S</given-names></name><name><surname>Tubach</surname><given-names>F</given-names></name><name><surname>Dechartes</surname><given-names>A</given-names></name></person-group><article-title>Meta-analysis frequently pooled different study types together: a meta-epidemiological study</article-title><source>J Clin Epidemiol</source><year>2020</year><volume>118</volume><fpage>18</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2019.10.013</pub-id><pub-id pub-id-type="pmid">31698062</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Bun RS, Scheer J, Guillo S, Tubach F, Dechartes A (2020) Meta-analysis frequently pooled different study types together: a meta-epidemiological study. J Clin Epidemiol 118:18&#x02013;28. 10.1016/j.jclinepi.2019.10.013<pub-id pub-id-type="pmid">31698062</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Golder</surname><given-names>S</given-names></name><name><surname>Loke</surname><given-names>YK</given-names></name><name><surname>Bland</surname><given-names>M</given-names></name></person-group><article-title>Meta-analysis of adverse effects data derived from randomized controlled trials as compared to observational studies: methodological overview</article-title><source>PLos Med</source><year>2011</year><volume>8</volume><issue>5</issue><fpage>e1001026</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1001026</pub-id><pub-id pub-id-type="pmid">21559325</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Golder S, Loke YK, Bland M (2011) Meta-analysis of adverse effects data derived from randomized controlled trials as compared to observational studies: methodological overview. PLos Med 8(5):e1001026. 10.1371/journal.pmed.1001026<pub-id pub-id-type="pmid">21559325</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>YD</given-names></name><name><surname>Jansen</surname><given-names>JP</given-names></name><name><surname>Guerino</surname><given-names>J</given-names></name><name><surname>Crown</surname><given-names>BML</given-names></name><name><surname>W, Goettsch WG, </surname></name></person-group><article-title>Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials</article-title><source>BMC Med</source><year>2021</year><volume>19</volume><issue>1</issue><fpage>307</fpage><pub-id pub-id-type="doi">10.1186/s12916-021-02176-1</pub-id><pub-id pub-id-type="pmid">34865623</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Hong YD, Jansen JP, Guerino J, Crown BML, W, Goettsch WG, (2021) Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials. BMC Med 19(1):307. 10.1186/s12916-021-02176-1<pub-id pub-id-type="pmid">34865623</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Kimachi</surname><given-names>M</given-names></name><name><surname>Onishi</surname><given-names>A</given-names></name><name><surname>Tajika</surname><given-names>A</given-names></name><name><surname>Kimachi</surname><given-names>K</given-names></name><name><surname>Furukawa</surname><given-names>TA</given-names></name></person-group><article-title>Systematic differences in effect estimates between observational studies and randomized controlled trials in meta-analysis in nephrology</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>6088</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-85519-5</pub-id><pub-id pub-id-type="pmid">33731727</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kimachi M, Onishi A, Tajika A, Kimachi K, Furukawa TA (2021) Systematic differences in effect estimates between observational studies and randomized controlled trials in meta-analysis in nephrology. Sci Rep 11(1):6088. 10.1038/s41598-021-85519-5<pub-id pub-id-type="pmid">33731727</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Hohmann</surname><given-names>E</given-names></name><name><surname>Feldman</surname><given-names>M</given-names></name><name><surname>Hunt</surname><given-names>TJ</given-names></name><name><surname>Cote</surname><given-names>MP</given-names></name><name><surname>Brand</surname><given-names>JC</given-names></name></person-group><article-title>Research pearls: how do we establish the level of evidence?</article-title><source>Arthroscopy</source><year>2018</year><volume>34</volume><issue>12</issue><fpage>3271</fpage><lpage>3277</lpage><pub-id pub-id-type="doi">10.1016/j.arthro.2018.10.002</pub-id><pub-id pub-id-type="pmid">30509436</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Hohmann E, Feldman M, Hunt TJ, Cote MP, Brand JC (2018) Research pearls: how do we establish the level of evidence? Arthroscopy 34(12):3271&#x02013;3277. 10.1016/j.arthro.2018.10.002<pub-id pub-id-type="pmid">30509436</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Mancino</surname><given-names>F</given-names></name><name><surname>Di Matteo</surname><given-names>V</given-names></name><name><surname>Mocini</surname><given-names>F</given-names></name><name><surname>Caccioloa</surname><given-names>G</given-names></name><name><surname>Malerba</surname><given-names>G</given-names></name><name><surname>Perisano</surname><given-names>C</given-names></name><name><surname>De Martino</surname><given-names>I</given-names></name></person-group><article-title>Survivorship of proximal femoral replacement in non-neoplastic primary and revision total hip arthroplasty: a systematic review</article-title><source>BMC Musculoskelet Disord</source><year>2021</year><volume>22</volume><issue>Suppl 2</issue><fpage>933</fpage><pub-id pub-id-type="doi">10.1186/s12891-021-04711-w</pub-id><pub-id pub-id-type="pmid">34749680</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Mancino F, Di Matteo V, Mocini F, Caccioloa G, Malerba G, Perisano C, De Martino I (2021) Survivorship of proximal femoral replacement in non-neoplastic primary and revision total hip arthroplasty: a systematic review. BMC Musculoskelet Disord 22(Suppl 2):933. 10.1186/s12891-021-04711-w<pub-id pub-id-type="pmid">34749680</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Hozo</surname><given-names>SP</given-names></name><name><surname>Djulbegovic</surname><given-names>B</given-names></name><name><surname>Hozo</surname><given-names>I</given-names></name></person-group><article-title>Estimating the mean and variance from the median, range, and the size of a sample</article-title><source>BMC Med Res Methodol</source><year>2005</year><volume>5</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1186/1471-2288-5-13</pub-id><pub-id pub-id-type="pmid">15840177</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. 10.1186/1471-2288-5-13<pub-id pub-id-type="pmid">15840177</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Bastos</surname><given-names>R</given-names></name><name><surname>Mathias</surname><given-names>M</given-names></name><name><surname>Andrade</surname><given-names>R</given-names></name><name><surname>Amaral</surname><given-names>RJFC</given-names></name><name><surname>Schott</surname><given-names>V</given-names></name><name><surname>Balduini</surname><given-names>A</given-names></name><etal/></person-group><article-title>Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial</article-title><source>Knee Surg Sports Traumatol Arthrosc</source><year>2020</year><volume>28</volume><issue>6</issue><fpage>1989</fpage><lpage>1999</lpage><pub-id pub-id-type="doi">10.1007/s00167-019-05732-8</pub-id><pub-id pub-id-type="pmid">31587091</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Bastos R, Mathias M, Andrade R, Amaral RJFC, Schott V, Balduini A et al (2020) Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial. Knee Surg Sports Traumatol Arthrosc 28(6):1989&#x02013;1999. 10.1007/s00167-019-05732-8<pub-id pub-id-type="pmid">31587091</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Freitag</surname><given-names>J</given-names></name><name><surname>Bates</surname><given-names>D</given-names></name><name><surname>Wickham</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Huguenin</surname><given-names>L</given-names></name><name><surname>Tenen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial</article-title><source>Regen Med</source><year>2019</year><volume>14</volume><issue>3</issue><fpage>213</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.2217/rme-2018-0161</pub-id><pub-id pub-id-type="pmid">30762487</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Freitag J, Bates D, Wickham J, Shah K, Huguenin L, Tenen A et al (2019) Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial. Regen Med 14(3):213&#x02013;230. 10.2217/rme-2018-0161<pub-id pub-id-type="pmid">30762487</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>KKW</given-names></name><name><surname>Lee</surname><given-names>WYW</given-names></name><name><surname>Griffith</surname><given-names>JF</given-names></name><name><surname>Ong</surname><given-names>MTY</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><etal/></person-group><article-title>Randomized controlled trial of mesenchymal stem cells versus hyaluronic acid in patients with knee osteoarthritis&#x02014;a Hong Kong pilot study</article-title><source>J Orthop Transl</source><year>2022</year><volume>37</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.jot.2022.07.012</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Ho KKW, Lee WYW, Griffith JF, Ong MTY, Li G et al (2022) Randomized controlled trial of mesenchymal stem cells versus hyaluronic acid in patients with knee osteoarthritis&#x02014;a Hong Kong pilot study. J Orthop Transl 37:69&#x02013;77. 10.1016/j.jot.2022.07.012</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Lamo-Espinosa</surname><given-names>JM</given-names></name><name><surname>Mora</surname><given-names>G</given-names></name><name><surname>Blanco</surname><given-names>JF</given-names></name><name><surname>Granero-Molto</surname><given-names>F</given-names></name><name><surname>Nunez-Cordoba</surname><given-names>JM</given-names></name><name><surname>Sanchez-Echenique</surname><given-names>C</given-names></name><etal/></person-group><article-title>Intra-articular injections of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled trial (Phase I/II)</article-title><source>J Trans Med</source><year>2016</year><volume>14</volume><issue>1</issue><fpage>246</fpage><pub-id pub-id-type="doi">10.1186/s12967-016-0998-2</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Molto F, Nunez-Cordoba JM, Sanchez-Echenique C et al (2016) Intra-articular injections of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled trial (Phase I/II). J Trans Med 14(1):246. 10.1186/s12967-016-0998-2</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Lamo-Espinosa</surname><given-names>JM</given-names></name><name><surname>Blanco</surname><given-names>JF</given-names></name><name><surname>Sanchez</surname><given-names>M</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name><name><surname>Granero-Molto</surname><given-names>F</given-names></name><name><surname>Sanchez-Guijo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis</article-title><source>J Transl Med</source><year>2020</year><volume>18</volume><issue>1</issue><fpage>356</fpage><pub-id pub-id-type="doi">10.1186/s12967-020-02530-6</pub-id><pub-id pub-id-type="pmid">32948200</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Lamo-Espinosa JM, Blanco JF, Sanchez M, Moreno V, Granero-Molto F, Sanchez-Guijo F et al (2020) Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis. J Transl Med 18(1):356. 10.1186/s12967-020-02530-6<pub-id pub-id-type="pmid">32948200</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>K-II</given-names></name><name><surname>Kim</surname><given-names>GB</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name></person-group><article-title>Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase IIB, randomized, placebo-controlled clinical trial</article-title><source>Stem Cells Transl Med</source><year>2019</year><volume>8</volume><issue>6</issue><fpage>504</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1002/sctm.18-0122</pub-id><pub-id pub-id-type="pmid">30835956</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Lee WS, Kim HJ, Kim K-II, Kim GB, Jin W (2019) Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase IIB, randomized, placebo-controlled clinical trial. Stem Cells Transl Med 8(6):504&#x02013;511. 10.1002/sctm.18-0122<pub-id pub-id-type="pmid">30835956</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>P</given-names></name></person-group><article-title>Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial</article-title><source>Stem Cells Res Ther</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>143</fpage><pub-id pub-id-type="doi">10.1186/s13287-019-1248-3</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Lu L, Dai C, Zhang Z, Du H, Li S, Ye P (2019) Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial. Stem Cells Res Ther 10(1):143. 10.1186/s13287-019-1248-3</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Schweich-Adami</surname><given-names>LC</given-names></name><name><surname>Silva</surname><given-names>RA</given-names></name><name><surname>Menezes</surname><given-names>JNS</given-names></name><name><surname>Baranoski</surname><given-names>A</given-names></name><name><surname>Kassuya</surname><given-names>CAL</given-names></name><name><surname>Bernardi</surname><given-names>L</given-names></name><etal/></person-group><article-title>The intra-articular injection of adipose-derived stem cells decreases pain and reduces inflammation in knee osteoarthritis, with or without the addition of platelet-rich plasma also improves functionality</article-title><source>J Tissue Eng Regen Med</source><year>2022</year><volume>16</volume><issue>10</issue><fpage>900</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1002/term.3337</pub-id><pub-id pub-id-type="pmid">35797223</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Schweich-Adami LC, Silva RA, Menezes JNS, Baranoski A, Kassuya CAL, Bernardi L et al (2022) The intra-articular injection of adipose-derived stem cells decreases pain and reduces inflammation in knee osteoarthritis, with or without the addition of platelet-rich plasma also improves functionality. J Tissue Eng Regen Med 16(10):900&#x02013;912. 10.1002/term.3337<pub-id pub-id-type="pmid">35797223</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Yokota</surname><given-names>N</given-names></name><name><surname>Hattori</surname><given-names>M</given-names></name><name><surname>Ohtsuru</surname><given-names>T</given-names></name><name><surname>Otsuji</surname><given-names>M</given-names></name><name><surname>Lynman</surname><given-names>S</given-names></name><name><surname>Shinomura</surname><given-names>K</given-names></name></person-group><article-title>Comparative clinical outcomes after intra-articular injection with adipose-derived cultured stem cells or noncultured stromal vascular fraction for the treatment of knee osteoarthritis</article-title><source>Am J Sports Med</source><year>2019</year><volume>47</volume><issue>11</issue><fpage>2577</fpage><lpage>2583</lpage><pub-id pub-id-type="doi">10.1177/0363546519864359</pub-id><pub-id pub-id-type="pmid">31373830</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Yokota N, Hattori M, Ohtsuru T, Otsuji M, Lynman S, Shinomura K (2019) Comparative clinical outcomes after intra-articular injection with adipose-derived cultured stem cells or noncultured stromal vascular fraction for the treatment of knee osteoarthritis. Am J Sports Med 47(11):2577&#x02013;2583. 10.1177/0363546519864359<pub-id pub-id-type="pmid">31373830</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>W</given-names></name><name><surname>Leng</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Ao</surname><given-names>Y</given-names></name></person-group><article-title>Intra-articular mesenchymal stromal cell injections are no different from placebo in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Arthroscopy</source><year>2021</year><volume>37</volume><issue>1</issue><fpage>340</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.arthro.2020.10.016</pub-id><pub-id pub-id-type="pmid">33098949</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Dai W, Leng X, Shi Z, Cheng J, Hu X, Ao Y (2021) Intra-articular mesenchymal stromal cell injections are no different from placebo in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Arthroscopy 37(1):340&#x02013;358. 10.1016/j.arthro.2020.10.016<pub-id pub-id-type="pmid">33098949</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Zou</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name></person-group><article-title>Clinical therapeutic efficacy of mesenchymal stem cells derived from adipose or bone marrow for knee osteoarthritis: a meta-analysis of randomized controlled trials</article-title><source>J Comp Eff Res</source><year>2020</year><volume>9</volume><issue>5</issue><fpage>361</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.2217/cer-2019-0187</pub-id><pub-id pub-id-type="pmid">32141308</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Han X, Yang B, Zou F, Sun J (2020) Clinical therapeutic efficacy of mesenchymal stem cells derived from adipose or bone marrow for knee osteoarthritis: a meta-analysis of randomized controlled trials. J Comp Eff Res 9(5):361&#x02013;374. 10.2217/cer-2019-0187<pub-id pub-id-type="pmid">32141308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>N</given-names></name><name><surname>Mak</surname><given-names>C</given-names></name><name><surname>Bojanic</surname><given-names>C</given-names></name><name><surname>To</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>W</given-names></name></person-group><article-title>Meta-analysis of adipose tissue derived cell-based therapy for the treatment of knee osteoarthritis</article-title><source>Cells</source><year>2021</year><volume>10</volume><issue>6</issue><fpage>1365</fpage><pub-id pub-id-type="doi">10.3390/cells10061365</pub-id><pub-id pub-id-type="pmid">34206010</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Agarwal N, Mak C, Bojanic C, To K, Khan W (2021) Meta-analysis of adipose tissue derived cell-based therapy for the treatment of knee osteoarthritis. Cells 10(6):1365. 10.3390/cells10061365<pub-id pub-id-type="pmid">34206010</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Issa</surname><given-names>MR</given-names></name><name><surname>Naja</surname><given-names>AS</given-names></name><name><surname>Bouji</surname><given-names>NZ</given-names></name><name><surname>Sagherian</surname><given-names>BH</given-names></name></person-group><article-title>The role of adipose-derived mesenchymal stem cells in knee osteoarthritis: a meta-analysis of randomized controlled trials</article-title><source>Ther Adv Musculoskelet Dis</source><year>2022</year><volume>14</volume><fpage>1759720X221146005</fpage><pub-id pub-id-type="doi">10.1177/1759720X221146005</pub-id><pub-id pub-id-type="pmid">36601089</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Issa MR, Naja AS, Bouji NZ, Sagherian BH (2022) The role of adipose-derived mesenchymal stem cells in knee osteoarthritis: a meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis 14:1759720X221146005. 10.1177/1759720X221146005<pub-id pub-id-type="pmid">36601089</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Muthu</surname><given-names>S</given-names></name><name><surname>Patil</surname><given-names>SC</given-names></name><name><surname>Jeyaraman</surname><given-names>N</given-names></name><name><surname>Jeyaraman</surname><given-names>M</given-names></name><name><surname>Gangadaran</surname><given-names>P</given-names></name><name><surname>Rajendran</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Comparative effectiveness of adipose-derived mesenchymal stromal cells in the management of knee osteoarthritis: a meta-analysis</article-title><source>World J Orthop</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>23</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.5312/wjo.v14.i1.23</pub-id><pub-id pub-id-type="pmid">36686284</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Muthu S, Patil SC, Jeyaraman N, Jeyaraman M, Gangadaran P, Rajendran RL et al (2023) Comparative effectiveness of adipose-derived mesenchymal stromal cells in the management of knee osteoarthritis: a meta-analysis. World J Orthop 14(1):23&#x02013;41. 10.5312/wjo.v14.i1.23<pub-id pub-id-type="pmid">36686284</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Xiang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Research and publication trends on knee osteoarthritis and cellular senescence: a bibliographic analysis</article-title><source>Front Physiol</source><year>2023</year><volume>14</volume><fpage>1269338</fpage><pub-id pub-id-type="doi">10.3389/fphys.2023.1269338</pub-id><pub-id pub-id-type="pmid">38046948</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Wang S, Yang J, Xiang R, Li C, Li J, Shen X et al (2023) Research and publication trends on knee osteoarthritis and cellular senescence: a bibliographic analysis. Front Physiol 14:1269338. 10.3389/fphys.2023.1269338<pub-id pub-id-type="pmid">38046948</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>NP</given-names></name><name><surname>Paillard</surname><given-names>FC</given-names></name><name><surname>Ekman</surname><given-names>E</given-names></name></person-group><article-title>Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions</article-title><source>J Orthop Surg Res</source><year>2015</year><volume>10</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/s13018-014-0144-x</pub-id><pub-id pub-id-type="pmid">25645576</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Katz NP, Paillard FC, Ekman E (2015) Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions. J Orthop Surg Res 10:24. 10.1186/s13018-014-0144-x<pub-id pub-id-type="pmid">25645576</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Mikkelsen</surname><given-names>RK</given-names></name><name><surname>Bl&#x000f8;nd</surname><given-names>L</given-names></name><name><surname>Rosenkrantz-H&#x000f6;lmich</surname><given-names>L</given-names></name><name><surname>M&#x000f8;lgaard</surname><given-names>C</given-names></name><name><surname>Troelsen</surname><given-names>A</given-names></name><name><surname>H&#x000f6;lmich</surname><given-names>P</given-names></name><etal/></person-group><article-title>Treatment of osteoarthritis with autologous, micro-fragmented adipose tissue: a study protocol for a randomized clinical trial</article-title><source>Trial</source><year>2021</year><volume>22</volume><issue>1</issue><fpage>748</fpage><pub-id pub-id-type="doi">10.1186/s13063-021-05628-4</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Mikkelsen RK, Bl&#x000f8;nd L, Rosenkrantz-H&#x000f6;lmich L, M&#x000f8;lgaard C, Troelsen A, H&#x000f6;lmich P et al (2021) Treatment of osteoarthritis with autologous, micro-fragmented adipose tissue: a study protocol for a randomized clinical trial. Trial 22(1):748. 10.1186/s13063-021-05628-4</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>J</given-names></name><name><surname>Lange</surname><given-names>T</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>KP</given-names></name><name><surname>Kopkow</surname><given-names>C</given-names></name><name><surname>Rataj</surname><given-names>E</given-names></name><name><surname>Apfelbacher</surname><given-names>C</given-names></name><etal/></person-group><article-title>Indication criteria for total knee arthroplasty in patients with osteoarthritis&#x02014;a multi-perspective consensus study</article-title><source>Z Orthop Unfall</source><year>2017</year><volume>155</volume><issue>5</issue><fpage>539</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1055/s-0043-115120</pub-id><pub-id pub-id-type="pmid">29050054</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Schmitt J, Lange T, G&#x000fc;nther KP, Kopkow C, Rataj E, Apfelbacher C et al (2017) Indication criteria for total knee arthroplasty in patients with osteoarthritis&#x02014;a multi-perspective consensus study. Z Orthop Unfall 155(5):539&#x02013;548. 10.1055/s-0043-115120<pub-id pub-id-type="pmid">29050054</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Spasovski</surname><given-names>D</given-names></name><name><surname>Spasnovski</surname><given-names>V</given-names></name><name><surname>Bascarevic</surname><given-names>Z</given-names></name><name><surname>Stojijlkovic</surname><given-names>M</given-names></name><name><surname>Andjelkovic</surname><given-names>M</given-names></name><name><surname>Pavlocic</surname><given-names>S</given-names></name></person-group><article-title>Seven-year longitudinal study: clinical evaluation of knee osteoarthritic patients treated with mesenchymal stem cells</article-title><source>J Clin Med</source><year>2024</year><volume>13</volume><issue>13</issue><fpage>3861</fpage><pub-id pub-id-type="doi">10.3390/jcm13133861</pub-id><pub-id pub-id-type="pmid">38999426</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Spasovski D, Spasnovski V, Bascarevic Z, Stojijlkovic M, Andjelkovic M, Pavlocic S (2024) Seven-year longitudinal study: clinical evaluation of knee osteoarthritic patients treated with mesenchymal stem cells. J Clin Med 13(13):3861. 10.3390/jcm13133861<pub-id pub-id-type="pmid">38999426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Jovic</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><etal/></person-group><article-title>A brief overview of global trends in MSC-based cell therapy</article-title><source>Stem Cell Rev Rep</source><year>2022</year><volume>18</volume><issue>5</issue><fpage>1525</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1007/s12015-022-10369-1</pub-id><pub-id pub-id-type="pmid">35344199</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Jovic D, Yu Y, Wang D, Wang K, Li H, Xu F et al (2022) A brief overview of global trends in MSC-based cell therapy. Stem Cell Rev Rep 18(5):1525&#x02013;1545. 10.1007/s12015-022-10369-1<pub-id pub-id-type="pmid">35344199</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>